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ABSTRACT OF DISSERTATION 
 
 
MOLECULAR MECHANISMS OF NEUROPILIN-LIGAND BINDING 
 
Neuropilin (Nrp) is an essential cell surface receptor with dual functionality in the 
cardiovascular and nervous systems. The first identified Nrp-ligand family was the 
Semaphorin-3 (Sema3) family of axon repulsion molecules. Subsequently, Nrp 
was found to serve as a receptor for the vascular endothelial growth factor (VEGF) 
family of pro-angiogenic cytokines. In addition to its physiological role, VEGF 
signaling via Nrp directly contributes to cancer stemness, growth, and metastasis. 
Thus, the Nrp/VEGF signaling axis is a promising anti-cancer therapeutic target. 
Interestingly, it has recently been shown that Sema3 and VEGF are functionally 
opposed to one another, with Sema3 possessing potent endogenous anti-
angiogenic activity and VEGF serving as an attractive cue for neuronal axons. We 
hypothesized that direct competition for an overlapping binding site within the Nrp 
extracellular domain may explain the observed functional competition between 
VEGF and Sema3. To test this hypothesis we have separately investigated the 
mechanisms of VEGF and Sema3 binding to Nrp. Utilizing structural biology 
coupled with biophysics and biochemistry we have identified both distinct and 
common mechanisms that facilitate the interaction between Nrp and these two 
ligand families. Specifically, we have identified an Nrp binding pocket to which 
these ligands competitively bind. The Sema3 family uniquely requires proteolytic 
activation in order to engage this overlapping binding site. These findings provide 
critical mechanistic insight into VEGF and Sema3 mediated physiology. 
Additionally, these data have informed the development of small molecules, 
peptides, and soluble receptor fragments that function as potent and selective 
inhibitors of VEGF/Nrp binding with exciting therapeutic potential for treating 
cancer. 
 
Keywords:  Neuropilin (Nrp), Vascular Endothelial Growth Factor (VEGF), 
Semaphorin-3 (Sema3), angiogenesis, axon guidance 
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CHAPTER 1: BACKGROUND AND INTRODUCTION 
Nrp Architecture 
 Neuropilin (Nrp) was first identified in the optic tectum of Xenopus and 
referred to as A5-antigen (Takagi et al., 1991; Takagi et al., 1987).  There are two 
conserved Nrp family members in vertebrates, Nrp1 and Nrp2, which share the 
same overall domain structure and are 44% identical at the amino acid level (Chen 
et al., 1997; Kolodkin et al., 1997).  Nrp family members are type I transmembrane 
proteins that possess an N-terminal signal peptide, two Ca2+-binding 
C1r/C1s/Uegf/Bmp1 (CUB) domains (a1a2) (Gaboriaud et al., 2011), two 
coagulation factor V/VIII-like discoidin domains (b1b2) (Fuentes-Prior et al., 2002; 
Kiedzierska et al., 2007), a Meprin/A5-antigen/ptp-Mu (MAM) domain (c), a single 
transmembrane helix, and a short intracellular domain.  The N-terminal four 
extracellular domains are necessary and sufficient for ligand binding.  The a1 
domain has been shown to interact with the sema domain of Sema3 ligands (Gu 
et al., 2002).  The b1 domain contains a specific C-terminal arginine binding pocket 
and is essential for binding to the C-terminal domain of both vascular endothelial 
growth factor (VEGF) and Semaphorin-3 (Sema3) ligands (Parker et al., 2010; 
Parker et al., 2012c; Starzec et al., 2007; Teesalu et al., 2009; Vander Kooi et al., 
2007; von Wronski et al., 2006).  Additionally, the b1 and b2 domains physically 
interact to form an extended patch of basic residues that is involved in binding 
heparin, a highly sulfated member of the glycosaminoglycan (GAG) family of 
carbohydrates (Vander Kooi et al., 2007).  The c domain is dispensable for ligand 
 2 
binding but essential for ligand-dependent signaling (Nakamura et al., 1998).  The 
transmembrane helix possesses a conserved GXXXG repeat and shows strong 
inherent dimerization potential (Roth et al., 2008).  The intracellular domain of Nrp 
interacts with PSD-95/Dlg/ZO-1 (PDZ)-domain proteins, such as GAIP Interacting 
Protein, C-terminus (GIPC), via its C-terminal residues (Cai and Reed, 1999).  
Deletion of the Nrp1 intracellular domain does not result in embryonic lethality, as 
seen with the whole gene, but instead causes defects in vascular patterning 
(Fantin et al., 2011).   
 There are alternative splice forms of Nrp1 and Nrp2 that have been shown 
to have functional implications.  The most commonly identified alternative splice 
forms of both Nrp1 and Nrp2 result from intron inclusion in the region between b2 
and c domains (Gagnon et al., 2000; Rossignol et al., 2000).  The included intron 
contains a stop-codon resulting in production of secreted soluble proteins that 
preserve ligand binding and thus function as endogenous pathway inhibitors.  
Alternative splicing of Nrp2 also produces two species with divergent C-terminal 
intracellular domains.  While multiple splice forms of both Nrp receptors exist, the 
functional significance of these divergent sequences is largely unknown.  In 
addition to splice variants, there are a number of post-translational modifications 
that alter Nrp function.  Nrp1 and Nrp2 can be modified by both N- and O-linked 
glycans.  Nrp1 has been shown to be modified by heparan- or chondroitin-sulfate 
which results in increased ligand binding (Shintani et al., 2006).  Thus, this 
modification may poise or pre-activate Nrp for signaling.  In contrast, Nrp2 is 
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modified by polysialic acid resulting in enhanced dendritic cell migration (Curreli et 
al., 2007; Rey-Gallardo et al., 2010). 
Nrp Function in Sema3 Dependent Axon Guidance 
 Nrp was initially identified and functionally characterized as a receptor for 
the Sema3 family ligands in neurons.  Neurons function in cooperative neural 
networks connected by dendrites and axons.  The number and type of axonal 
connections are tightly regulated by guidance cues.  One family of essential axon 
guidance molecules are the Semaphorins.  There are seven Sema3 family 
members (Sema3A-G) that are secreted, diffuse through tissues, and provide 
guidance cues (Kolodkin et al., 1993).  Indeed, axon guidance cues mediated by 
Sema3 family members are essential during development for correct neuronal 
patterning in dorsal root ganglia, facial, vagal, olfactory-sensory, cortical, 
hippocampal, and cerebellar nerves, along with others (Koncina et al., 2007).  
 Sema3 family members bind Nrp receptors on the cell surface (He and 
Tessier-Lavigne, 1997; Kolodkin et al., 1997) (Figure 1.1).  The N-terminal a1 
domain of Nrp1 and Nrp2 selectively binds the sema domain of different Sema3 
family members (Chen et al., 1998; Koppel et al., 1997; Merte et al., 2010).  
Notably, Sema3A specifically signals via Nrp1 (He and Tessier-Lavigne, 1997; 
Kolodkin et al., 1997) and Sema3F via Nrp2 (Giger et al., 1998). The Nrp b1 
domain allows high-affinity non-selective binding to the Sema3 C-terminal domain 
(Giger et al., 1998; Nakamura et al., 1998; Parker et al., 2010).  Following Sema3 
binding by Nrp, Plexin family signaling receptors (PlexinA1-4) are then engaged 
and activated to directly guide axonal growth (Puschel, 2002; Takahashi et al., 
 4 
1999).  Nrp functions by coupling specific high-affinity Sema3 binding to Plexin-
dependent regulation of cytoskeleton dynamics in the axonal growth cone 
(Takahashi et al., 1999).  Collapse of the actin cytoskeleton results in axon 
repulsion and this appears to represent the most common modality for Nrp-
dependent Sema3 function.  However, Sema3 signaling can also be attractive 
rather than repulsive, such as when cGMP levels are high (Song et al., 1998).  
Sema3 functionality also drives the pathological repulsion of axons following spinal 
cord injury where fibroblasts, which invade the glial scar, secrete members of the 
Sema3 family and prevent regrowth of axons. Thus, inhibition of the Sema3/Nrp 
signaling axis represents a promising therapeutic modality for functional recovery 
following spinal cord injury (De Winter et al., 2002; Fawcett, 2006; Pasterkamp et 
al., 1999).  
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Figure 1.1: Nrp function is essential for Sema3 dependent axon guidance. 
Nrps specifically bind to Sema3 family members through a bivalent binding 
mechanism allowing both specific and high-affinity binding.  Engagement and 
activation of Plexin family receptors activates signaling in both physiological axon 
guidance and pathological spinal cord injury.  Structures of proteins or homologues 
with known structures were utilized including: Semaphorin N-terminus: PDB=1OLZ 
(Love et al., 2003); Nrp N-terminal domains: PDB=2QQK (Appleton et al., 2007); 
Plexin extracellular domain N-terminus: PDB=3OKT (Janssen et al., 2010); Plexin 
intracellular domain: PDB=3IG3 (He et al., 2009). 
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Nrp Function in VEGF Dependent Angiogenesis 
 Angiogenesis is the process by which new vasculature is formed by 
branching or splitting from existing vasculature. Physiological angiogenesis is 
critical during development, for homeostatic maintenance of vasculature, and 
wound healing.  Among the most potent pro-angiogenic cytokine families is the 
VEGF family.  VEGF-A was the first identified family member (Ferrara and Henzel, 
1989; Senger et al., 1983), which also includes VEGF-B, -C, D, and placental 
growth factor (PlGF) (Ferrara et al., 2003).  The different family members have 
both unique and partially overlapping functions.  VEGF-A, -B and PlGF regulate 
hemangiogenesis by Nrp1 (Migdal et al., 1998; Soker et al., 1998; Zhang et al., 
2009).  VEGF-C and -D regulate lymphangiogenesis by Nrp2 (Mattila et al., 2002).  
Also, VEGF-B has recently been shown to control lipid transport in endothelial cells 
by Nrp1 (Hagberg et al., 2010).  To add to the complexity, VEGF-A, -B, and PlGF 
all have numerous alternative splice forms with varying physical and functional 
properties (Leung et al., 1989; Nowak et al., 2008) whereas VEGF-C and -D 
require proteolytic processing from a pre-protein for activation (Joukov et al., 
1997).  Nrp1 was initially identified as a VEGF-A165 splice-form specific receptor 
(Soker et al., 1998).  More recent work has demonstrated that Nrp1 can also bind 
other VEGF-A isoforms (Pan et al., 2007b; von Wronski et al., 2007) yet uniquely 
and specifically physically engages VEGF-A165 (Parker et al., 2012c). 
 VEGF-A is secreted by an initiating tissue, typically in response to hypoxia, 
and diffuses to nearby vessels where it binds to two families of essential 
endothelial cell-surface receptors: VEGF-receptor (VEGFR) tyrosine kinases 
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(Ferrara et al., 2003) and Nrps (Migdal et al., 1998; Soker et al., 1998) (Figure 1.2).  
VEGF-A binding causes initiation of the angiogenic cascade, which involves 
activation of endothelial cells, basement membrane remodeling, proliferation of 
endothelial cells, and directional guidance leading to the growth of new vasculature 
towards the initiating tissue.  Importantly, angiogenic signaling is only 
accomplished through the coordinated activity of VEGF, VEGFR, and Nrp 
(Klagsbrun et al., 2002).  While VEGF binding to VEGFR weakly activates its 
intracellular kinase activity, Nrp is required for strong and sustained kinase 
activation leading to initiation of the pro-angiogenic cascade (Becker et al., 2005; 
Soker et al., 2002).  Nrp1 null mice die in utero due to defective vasculature 
formation, thus emphasizing the critical role of Nrp in angiogenesis (Kitsukawa et 
al., 1997).  Importantly, abnormalities associated with loss of Nrp1 are caused by 
defective endothelial cell migration rather than proliferation (Jones et al., 2008). 
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Figure 1.2: Nrp function is essential for VEGF dependent angiogenesis. 
Nrps specifically bind to the C-terminal basic domain of VEGF family members.  
Cooperative binding of VEGF by VEGFR and Nrp activates the angiogenic 
cascade necessary for developmental and homeostatic angiogenesis and also 
pathological signaling associated with tumorigenesis and other types of aberrant 
signaling.  Structures of proteins with known structures were utilized including: 
VEGF-A cystine knot domain: PDB=2VPF (Muller et al., 1997); VEGF-A basic 
domain: PDB=4DEQ (Parker et al., 2012c); Nrp N-terminal domains: PDB=2QQK 
(Appleton et al., 2007); VEGFR2 Ig-like domain 2-3: PDB=2X1X (Leppanen et al., 
2010); VEGFR2 Ig-like domain 7: PDB=3KVQ (Yang et al., 2010); VEGFR2 
intracellular domain: PDB=1VR2 (McTigue et al., 1999). 
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Ligand Mediated Cross-Talk 
 Intriguingly, it has been noted that blood vessels and nerves utilize similar 
signals and principles for guidance (Adams and Eichmann, 2010; Arese et al., 
2011; Carmeliet, 2003).  Indeed, recent studies have identified an embryonic stem 
cell-derived population of cells that differentiate towards either vascular or 
neuronal cell-type depending on the microenvironment (Gualandris et al., 2009).  
Nrp receptors are expressed in nerves and endothelial cells, and both cell types 
are responsive to secreted ligands of the Sema3 and VEGF families (Erskine et 
al., 2011; Miao et al., 1999; Schwarz et al., 2004).  Not only are both cell types 
responsive to each family of ligands, but the different ligands can compete for Nrp 
binding (Figure 1.3). 
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Figure 1.3: Cross-talk between Nrp ligands allows coordinated regulation of 
neuronal and vascular tissues.  
Both neurons and endothelial cells express Nrp which can respond to either 
Sema3 or VEGF family guidance cues.  Regulation of competitive Nrp binding 
between different ligands allows for an additional level of dominant control of Nrp 
function. 
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Nrp in Tumor Angiogenesis 
 Nrp function is important not only for physiological angiogenesis but also in 
VEGF-dependent pathological hyper-vascularization in tumor angiogenesis (Bagri 
et al., 2009). It has long been known that the extent of tumor vascularization is 
correlated to tumor size (Algire and H.W., 1945) and that diffusible factors are able 
to induce neovascularization in solid tumors (Greenblatt and Shubi, 1968).  Anti-
angiogenesis therapies (Folkman, 1971) are now used against a range of solid 
tumors.  Avastin, a monoclonal antibody targeting VEGF-A, has been among the 
most successful angiogenesis inhibitors (Ferrara et al., 2005).  While providing 
significant benefit it has been noted that when patients relapse, those that received 
anti-angiogenesis treatment often have more aggressive and metastatic tumors 
(Ebos et al., 2009; Paez-Ribes et al., 2009).  Aberrant Nrp expression and function 
promotes tumorigenesis and metastasis in vivo in a variety of solid tumors 
(Bielenberg et al., 2006; Ellis, 2006; Guttmann-Raviv et al., 2006; Klagsbrun et al., 
2002).  Surprisingly, in addition to expression in tumor vasculature, direct Nrp 
overexpression in malignant cells has been widely reported. 
Nrp Tumor Cell Expression and Autocrine Activation 
 The initial identification of Nrp as a receptor for VEGF noted its expression 
in both endothelial and tumor cells (Soker et al., 1998).  Since then, aberrant Nrp 
expression in a wide variety of malignant cells has been observed (Banerjee et al., 
2000; Kreuter et al., 2006; Miao et al., 2000; Stephenson et al., 2002; Vacca et al., 
2006).  The function of Nrp in tumor cells, and its contribution to tumorigenesis, is 
the source of considerable interest.  Recently, Nrp expression was demonstrated 
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to be critical for autocrine activation of tumor cells, influencing carcinoma survival 
(Bachelder et al., 2001), growth (Cao et al., 2012), and migration (Bachelder et al., 
2003; Bagci et al., 2009).  Nrp-dependent autocrine activation provides a basis for 
understanding why Nrp expression and function directly correlates to both tumor 
aggressiveness (Goel et al., 2013) and the metastatic potential of a variety of solid 
tumors (Latil et al., 2000; Ochiumi et al., 2006).  Further, Nrp function in tumor cells 
has been tied to dedifferentiation and stemness (Cao et al., 2008).  It has recently 
been shown that Nrp1 directly contributes to the self-renewal of cancer stem cells 
in skin cancer (Beck et al., 2011).  Indeed, Nrp1 deletion blocked the ability of 
VEGF to promote cancer stem cell self-renewal.  Further, an autocrine activation 
pathway involving Nrp1 was shown to contribute to stem-like cell viability and 
tumor growth in glioma (Hamerlik et al., 2012). The multi-functional role for Nrp in 
tumor initiation and progression has motivated research focusing on developing 
novel Nrp inhibitory modalities. Additionally, as the genetic profile of various tumors 
is characterized it will be interesting to determine whether there are specific gain-
of-function mutations within the Nrp gene that further contribute to its tumorigenic 
activity. 
General Modes of Nrp Action 
 Nrps are normally expressed in a variety of tissue types including the 
previously discussed nerves and vascular tissues along with immune and 
hematopoietic cells (Tordjman et al., 2002; Yamada et al., 2003).  In addition to 
the critical role for Nrp in the Sema3 and VEGF pathways, interactions with a 
number of other ligands and receptors have been reported.  Other ligands 
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identified include members of the fibroblast growth factor (FGF) family, platelet-
derived growth factor (PDGF), transforming growth factor β1 (TGF- β1), and 
hepatocyte growth factor/scatter factor (HGF/SF) functioning via receptors in the 
FGFR, PDGFR, TβRs and c-Met families, respectively (Banerjee et al., 2006; Cao 
et al., 2010a; Cao et al., 2010b; Glinka and Prud'homme, 2008; Goel et al., 2013; 
Holmes and Zachary, 2008; Hu et al., 2007; Matsushita et al., 2007; West et al., 
2005). In light of the diverse expression profile and functional interactions, 
determining the general mechanism(s) of Nrp action is critical to further our 
understanding of physiological and pathological functions of Nrp. 
Nrp Functions by Physically Organizing the Full Signaling Complex 
 As a primary function, Nrps promote pathway activation by recruiting ligands 
to the cell surface through high-affinity interactions (Figure 1.4, A).  This is 
particularly important in Sema3 binding, which is the only diffusible Sema family 
and requires Nrp for cell-surface binding (Zhou et al., 2008).  Additionally, Nrps 
show selective binding to different members within the VEGF and Sema3 families. 
The basis for specific Nrp1-VEGF-A interactions in hemangiogenesis has been 
described biochemically and structurally (Geretti et al., 2007; Parker et al., 2012b), 
and other family members are actively being pursued. 
 Ligand binding is followed by assembly of the active signaling complex, 
where Nrp functions to promote and stabilize the active signaling holoenzyme 
(Shraga-Heled et al., 2007; Soker et al., 2002; Takahashi et al., 1999) (Figure 1.4, 
B).  Assembly of the active signaling complex requires both receptor recruitment 
and binding associated conformational changes, providing the physical 
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mechanism required for signal transduction.  Importantly, Nrp ligands are dimeric, 
with conserved intermolecular disulfide bonds.  Thus, the minimum signaling 
holocomplex is thought to involve a dimeric ligand bound to two Nrp molecules and 
two signaling receptors.  Energetically, it appears that highly favorable ligand 
binding drives the formation of specific homo- and hetero-typic receptor contacts 
that do not occur spontaneously (Brozzo et al., 2012; Fuh et al., 2000).  This is 
consistent with optimal receptor function, with physical mechanisms strongly 
inhibiting spontaneous ligand-independent activation.  
Understanding Nrp function in holocomplex assembly requires knowledge 
of the structure and interactions of the receptor both before and after ligand 
binding.  The a2b1b2 domains of Nrp have been reported to adopt a stably 
associated trimeric core with loosely tethered a1 domain (Appleton et al., 2007).  
The c/MAM domain, which is dispensable for ligand binding but essential for 
ligand-induced signaling (Nakamura et al., 1998), has been reported to form homo- 
and hetero-dimers between Nrp1 and Nrp2 (Chen et al., 1998).  However, 
experiments with purified protein have reported that there is no self-association or 
dimerization propensity observable for the Nrp ectodomain, leaving the structure 
and physical coupling of the MAM domain within Nrp an open question (Appleton 
et al., 2007).  
 GAG binding also plays a critical role in Nrp-dependent signaling.  GAGs 
are a diverse family of naturally occurring sulfated polysaccharides that orchestrate 
numerous processes including the function of endothelial cells in angiogenesis 
(Stringer, 2006).  GAG binding dramatically enhances Nrp-ligand interactions and 
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drives dimerization of Nrp (Fuh et al., 2000; Vander Kooi et al., 2007).  Thus, GAG 
binding likely plays a dual role by bridging and stabilizing the dimer holocomplex 
assembly. 
 Intriguingly, a number of receptors have been shown to associate with Nrp 
in a ligand independent fashion.  A direct and specific interaction has been 
demonstrated between Nrp1 and VEGFR1 (Fuh et al., 2000).  Nrp and Plexin 
family receptors have also been shown to associate in a ligand independent 
manner (Takahashi and Strittmatter, 2001). In these cases, rather than having 
sequential receptor binding, the pre-associated receptor complex is poised to bind 
and signal and only requires conformational changes (Figure 1.4, C).   
Nrp Trafficking 
 Following ligand binding and assembly of the active signaling complex, Nrp 
has been demonstrated to have a critical function in receptor trafficking (Figure 
1.4, D).  Intriguingly, it was shown that Sema3 and VEGF induce Nrp1 endocytosis 
via distinct pathways (Salikhova et al., 2008).  Further, Nrp promotes the 
partitioning of VEGFR into vesicles that are recycled back to the cell surface, 
whereas in the absence of Nrp, VEGFR2 is targeted for degradation instead of 
recycling (Ballmer-Hofer et al., 2011). The intracellular GIPC-binding domain of 
Nrp was demonstrated to be essential for the observed VEGFR recycling, 
suggesting the involvement of a Nrp-associated cytoplasmic protein. 
The Nrp Intracellular Domain 
 The discovery of the Nrp-binding PDZ-protein GIPC provided a mechanism 
by which Nrp may directly couple to intracellular adaptors and pathways (Cai and 
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Reed, 1999) (Figure 1.4, E).  The critical portion of the Nrp intracellular domain is 
the three C-terminal amino acids, conserved in Nrp1 and Nrp2, that constitute a 
PDZ-binding motif and allow binding to PDZ-domain proteins.  Increasing evidence 
implicates the intracellular domain of Nrp in a variety of biological processes.  Mice 
expressing a mutant Nrp receptor with deleted cytoplasmic domain were 
generated (Fantin et al., 2011).  While capable of binding ligand, these Nrp 
receptors are decoupled from signal transduction via its PDZ-binding motif and 
GIPC and result in vascular abnormalities distinct from those of full Nrp1 knockout. 
Angiogenesis was unaffected but vascular patterning was disrupted as evidenced 
by frequent crossing of arteries and veins in the retina.  A similar approach was 
applied in zebrafish, demonstrating that knockdown of Nrp1 does disrupt 
angiogenesis and only full length Nrp, not a Nrp1 construct lacking the three C-
terminal amino acids, is able to rescue disrupted blood vessel growth (Wang et al., 
2006).  Further, deletion of the PDZ-binding C-terminal amino acids of Nrp1 
disrupted stable association of the full angiogenic signaling complex with VEGFR-
2 (Prahst et al., 2008). There is also growing evidence for Nrp function in the 
absence of other recognized receptor families. Specifically, Nrp is capable of 
mediating adhesiveness (Murga et al., 2005) and migration (Wang et al., 2003) of 
endothelial cells in the absence of VEGFR2, functions that require the C-terminal 
PDZ-binding motif of the Nrp intracellular domain.  
 Interaction with a common intracellular adaptor, such as GIPC, suggests 
that Nrp function in physiologically diverse pathways may be due to coupling to 
basic cellular signaling pathways. Intriguingly, the integrin subunits α6 and α5 have 
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been reported to interact with GIPC via their C-terminus (Tani and Mercurio, 2001), 
(El Mourabit et al., 2002). 
Nrp Coupling with Integrins 
 Integrins mediate interactions with the extracellular matrix and as a result 
are important for cellular adhesion and migration.  Indeed, the biological function 
first associated with Nrp1 was its ability to mediate heterophilic cellular adhesion 
(Takagi et al., 1995). A variety of studies have now demonstrated that both Nrp1 
and Nrp2 physically and functionally associate with integrins (Fukasawa et al., 
2007; Goel et al., 2012; Serini et al., 2003) (Figure 1.4, F).   
 Exogenous Sema3 was able to inhibit the adhesion of endothelial cells to 
the integrin ligands fibronectin and vitronectin, while VEGF enhanced the adhesive 
strength of endothelial cells (Serini et al., 2003).  Furthermore, a recent study 
demonstrated that Nrp1 was necessary for endothelial cell adhesion to fibronectin 
(Valdembri et al., 2009). Surprisingly, rescue of fibronectin binding following Nrp1 
knockdown was only seen using vectors carrying full-length Nrp but not Nrp 
constructs lacking the C-terminal PDZ-binding motif, suggesting coupling between 
integrin and PDZ-domain proteins.  αvβ3 integrin has been shown to interact with 
Nrp1 in a VEGF-dependent fashion and this serves to sequester Nrp1 from the 
active VEGF/VEGFR2 signaling complex thereby limiting angiogenesis (Robinson 
et al., 2009).  The function of integrins in controlling cellular migration led to 
investigation of the interplay between Nrp1 and integrin β1, demonstrating that 
blockade of either Nrp1 or β1 resulted in reduced invasiveness and adhesion in a 
pancreatic cancer cell line (Fukasawa et al., 2007).  Recently, an important specific 
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role for Nrp2 in integrin-mediated adhesion has also been defined.  Nrp2 makes 
specific interactions with integrin α6β1 at focal adhesion sites. Depleting Nrp2 
expression in breast carcinoma cells inhibited focal adhesion assembly of these 
cells and regulated the downstream targets of α6β1 integrin that ultimately 
modulate laminin adhesion (Goel et al., 2012). These data demonstrate that Nrp 
and integrin receptors function cooperatively to regulate cellular adhesion and 
there is considerable interest in understanding the precise nature of the physical 
coupling and extent of biological function.   
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Figure 1.4: Nrp utilizes common mechanisms to regulate diverse signaling 
pathways.  
A) Specific high-affinity ligand binding initiates Nrp mediated signaling.  B) 
Engagement and organization of an active signaling complex is accomplished 
through specific receptor-ligand and co-receptor contacts.  C) Ligand-independent 
receptor association forms a pre-activated receptor complex poised for signaling.  
D) Nrp regulates dynamic trafficking of signaling complexes.  E) Binding of 
intracellular PDZ-domain proteins, including GIPC, allow direct coupling between 
Nrp ligand binding and signaling functions.  F) Direct engagement of integrins 
allows Nrp to couple molecular events with cellular cues. 
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Scope of Dissertation 
As previously discussed, the b1 domain of Nrp is responsible for binding the C-
terminal domain of both VEGF and Sema3.  Three coagulation-factor loops of the 
b1 domain form a conserved binding pocket specific for C-terminal arginine 
containing ligands (Lee et al., 2003; Parker et al., 2012c; Vander Kooi et al., 2007).  
All VEGF family members possess a C-terminal arginine, which is necessary for 
binding to Nrp.  In contrast, no Sema3 family members possess a C-terminal 
arginine.  However, all Sema3 family members contain furin-like protease RXXR 
consensus sites in their C-terminal domain (Adams et al., 1997). The interplay of 
VEGF and Sema3 is important for diseases associated with angiogenesis.  
Aberrant hypo-vascularization was recently demonstrated in the retina where 
expression of Sema3A prevents revascularization of ischemic neural tissue (Joyal 
et al., 2011).  In contrast, aberrant hyper-vascularization is associated with VEGF 
upregulation or Sema3 downregulation in pathological angiogenesis of solid 
tumors (Neufeld et al., 2005; Sakurai et al., 2012; Vacca et al., 2006).  
 In order to gain an understanding of the complex physiological interplay 
between VEGF and Sema3, this dissertation aimed to understand both the distinct 
and overlapping mechanisms utilized by Nrp to bind these two ligand families. In 
Chapters 3-4 we describe the molecular basis for Sema3 binding to Nrp, which is 
regulated by C-terminal proteolysis (Parker et al., 2010; Parker et al., 2013). In 
Chapters 5-6 we investigate the physical mechanisms of Nrp1/VEGF-A and 
Nrp2/VEGF-C binding using structural biology and biochemistry (Parker et al., 
2012c). Finally, we merge this knowledge in the concluding Chapters (Chapters 7-
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8) to investigate the use of peptides, soluble receptor fragments, and small 
molecules as inhibitors of Nrp-ligand binding that hold significant therapeutic 
promise (Parker and Vander Kooi, 2014; Parker et al., 2012b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted in full or part with permission from: Function of Members of the 
Neuropilin Family as Essential Pleiotropic Cell Surface Receptors. Matthew 
W. Parker, Hou-Fu Guo, Xiaobo Li, Andrew D. Linkugel, and Craig W. Vander 
Kooi, Biochemistry 2012 51 (47), 9437-9446. Copyright 2012 American Chemical 
Society. 
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CHAPTER 2: MATERIALS AND METHODS 
Protein expression and purification 
 Human Nrp2-b1b2 (residues 276-595), human Nrp1-b1b2 (274-584), a 
fusion of human Nrp1-b1 (274-429) linked to the VEGF-A HBD (115-165) with an 
intervening Sal1 restriction site and 3X(GS), human Nrp2-b1 (residues 276-430), 
human Nrp2-T319R (residues 276-595 with T319R mutation), human Nrp1-
T316R, s9Nrp2B (residues 275-547 plus the unique intron-encoded C-terminal 
insertion: VGCSWRPL) and the Nrp2-b1b2/VEGF-C fusion were expressed as 
hexa-histidine fusion proteins from pET28b in E. coli strain Rosetta Gami-2(DE3) 
(Novagen/EMD Millipore, Billerica, MA). Nrp2-T319R and Nrp1-T316R were 
generated by megaprimer mutagenesis (Vander Kooi, 2013). To generate the 
Nrp2/VEGF-C fusion, the five C-terminal residues of VEGF-C (223-SIIRR-227) 
were appended to the C-terminus of Nrp2-b1b2 (276-595) by incorporating the 
VEGF-C sequence into the reverse primer during cloning.  Likewise, generation of 
s9Nrp2B involved primer incorporation of the sequence VGCSWRPL C-terminal to 
residues 275-547. All constructs and mutations were sequence verified.  Cells 
were grown in terrific broth and cold shocked at an OD600 = 1.5. Following induction 
with 1 M IPTG, cells were grown overnight at 16°C. Harvested cells were lysed by 
sonication and lysozyme treatment and proteins were purified via immobilized 
metal ion affinity chromatography (IMAC) (HIS-Select HF Nickel Affinity Gel, 
Sigma-Aldrich, St. Louis, MO) and eluted with 300 mM Imidazole, 200 mM NaCl. 
Nrp2-b1b2, Nrp2-T319R, and the fusion protein were subsequently subjected to 
heparin affinity chromatography (HiTrap Heparin HP, GE Healthcare Life 
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Sciences, Pittsburgh, PA).  Nrp2-b1 and s9Nrp2B, which were incubated for 48 
hours to facilitate production of the disulfide-linked dimer, were further purified by 
size exclusion chromatography using a Superdex75 HiLoad 16/60 column (GE 
Healthcare Life Sciences) equilibrated and run with 20 mM Tris pH 7.5, 100 mM 
NaCl.  
Alkaline-phosphatase tagged mouse VEGF-A164 (residues 27-190) (AP-VEGF-
A164), AP-VEGF-A164 mutants, human AP-VEGF-A165 (residues 27-191), mouse 
AP-VEGF-C (residues 108-223), AP-VEGF-C R223E, human AP-Sema3F 
(residues 20-779), and the Ig-Basic domain of human Sema3F (residues 605-779) 
were expressed in Chinese Hamster Ovary (CHO) cells via large-scale transient 
transfection from pAPtag-5 vector (GenHunter, Nashville, TN)(Parker et al., 2010). 
The C-terminal Nrp binding region of human Sema3F (residues 605-785 (Gu et 
al., 2002)) was produced as a C-terminal or an N-terminal Human Growth 
Hormone (Hgh) fusion from the pLexM vector (Aricescu et al., 2006; Leahy et al., 
2000).  Protein was produced from CHO, furin deficient FD11, and furin 
overexpressing cells (Gordon et al., 1995).  Protein was also produced in COS-7 
cells in the absence and presence of Dec-RVKR-CMK and D-poly-Arg-NH2 furin 
inhibitors (Calbiochem, San Diego, CA).  Cells were maintained in a-MEM 
supplemented with 5% FBS.  For protein expression, cells were transferred to 
Hybridoma-SFM media (Invitrogen, Carlsbad, CA) when they reached 80% 
confluence and transfected with PEI-MAX (Polysciences Inc., Warrington, PA) 
using 1mg DNA/mL media and a 3:1 PEI:DNA ratio. 
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Differential scanning fluorimetry (DSF)  
Peptides corresponding to processed (RQVHSIIRR) and unprocessed 
(RQVHSIIRRSLPA) VEGF-C were produced with an N-terminal tryptophan for 
quantitation by UV280 absorbance (LifeTein LLC, Hillsborough, NJ). Peptides were 
resuspended and combined with 2 μM of Nrp2-b1b2 and 5x SYPRO Orange 
Protein Gel Stain (Life Technologies, Grand Island, NY) in PBS. Nrp2-b1b2 melting 
was monitored on a CFX96 Real-Time PCR system (BioRad, Hercules, CA) from 
20 to 90°C at a rate of 1°C/50s with fluorescent readings taken every 1°C. 
Structure determination 
For crystallization, the His-tag was removed from all proteins after IMAC 
purification by overnight incubation with thrombin. Purified Nrp2-b1b2-VEGF-C 
fusion in 250 mM NaCl, 10 mM Tris pH 7.5, Nrp2-T319R in 100 mM NaCl, 5 mM 
Tris pH 7.5, and s9Nrp2B in 100 mM NaCl, 20 mM Tris pH 7.5 were concentrated 
to 2.0 mg/mL, 2.1 mg/mL and 3.5 mg/mL, respectively, and crystals were grown 
by hanging-drop vapor-diffusion experiments at RT. Crystals of the fusion protein 
were obtained in two weeks in 0.1 M MES pH 6.5, 0.5 M Ammonium Sulfate. Nrp2-
T319R crystals were obtained in five days in 0.1 M HEPES pH 7, 18% (w/v) PEG 
12000 and crystals of s9Nrp2B were grown in 10% PEG 1000/10% PEG 8000. The 
Nrp-VEGF-A HBD fusion protein was concentrated to 5mg/mL and mixed in a 3:1 
ratio of protein to mother liquor containing 1.5M Na/K phosphate pH=6.5.  Crystals 
formed in 1-2 weeks at 23°C. Crystals were passed through mother liquor 
supplemented with 10% glycerol and then flash frozen in liquid nitrogen. Diffraction 
data were collected at the SER-CAT 22-ID and 22-BM beamlines of the Advanced 
 25 
Photon Source, Argonne National Laboratories. Data were processed using 
HKL2000 (Otwinowski and Minor, 1997) (Table 1).   
 The structure of the Nrp2-b1b2-VEGF-C fusion and Nrp2-T319R were 
solved by molecular replacement with wild-type Nrp2-b1b2 (PDB code = 2QQJ) 
used as a search model. The b1 domain residues of 2QQJ (residues 276-427) 
were used as a search model for the s9Nrp2B molecular replacement solution. An 
initial molecular replacement solution for the Nrp-VEGF-A HBD fusion protein was 
obtained using PHASER with Nrp1-b1 (PDB=2QQI) as the search model (McCoy 
et al., 2007).  Clear electron density for the VEGF-A HBD was observed and 
manually built. 
 Following molecular replacement, iterative modeling building and 
refinement was done using COOT (Emsley et al., 2010) and Refmac5 (Murshudov, 
1997) to generate a final refined model (Table 1). To characterize intermolecular 
interactions, the structures were analyzed using the PISA interaction server 
(http://www.ebi.ac.uk/ msd-srv/prot_int/pistart.html) and Ligplot+ (Laskowski and 
Swindells, 2011). Protein geometry was analyzed using MolProbity (Chen et al., 
2010) and Superpose was used to calculate a difference density matrix (DDM) for 
the apo-Nrp2-b1b2 and complex structure (Maiti et al., 2004). Graphics were 
prepared with Pymol molecular graphics software (www.pymol.org).  
 The atomic coordinates and structure factors have been deposited in the 
Protein Data Bank (PDB), www.pdb.org. 
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Affinity pull-down   
Nrp2 was coupled to AffiGel (Bio-Rad, Hercules, CA) according to manufacturer’s 
recommendation at 5 mg protein/mL resin.  N-terminally tagged Sema3F Ig-basic 
was expressed in Cos-7 cells with and without furin inhibitors.  200mL of 
conditioned media was diluted to 1 mL with Buffer A (20 mM Tris, pH=7.5, 100 mM 
NaCl) and incubated with 100 mL of Nrp2 affinity resin for thirty minutes.  Resin 
was washed three times with Buffer A, and then eluted using 1 M NaCl.  Eluted 
protein was resolved using SDS-PAGE and visualized by western blot. 
Fluorescence Aniosotropy 
C-furSema was synthesized with an N-terminal Fluorescein isothiocyanate (FITC) 
(Genscript).  The peptide was resuspended and buffer exchanged into Buffer A.  
1.8 mM FITC C-furSema was combined with increasing concentrations of Nrp2 
and Nrp1.  Fluorescence anisotropy was measured at 23C using a SpectraMax 
M5 (Molecular Devices, Sunnyvale, CA) with excitation at 485 nm, emission at 525 
nm, and an emission filter at 515 nm).  Anisotropy was calculated from the average 
of three independent samples at each point using the experimentally determined 
G-factor of 1.113.  Dissociation constants (Kd) were calculated by fitting the data 
with Kaleida-Graph (Synergy Software, Reading, PA) using a single site model: 
 
where ro is the initial anisotropy and ra is the difference in anisotropy between 
bound and free species.  
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In vitro plate binding assay 
Nrp1 affinity plates were produced by diluting Nrp1-b1b2 to either 50, 25, or 2.5 
ng/μl in 50 mM Na2CO3 pH 10.4 and 100 μl was added to 96 well protein high-
binding plates (Costar, 9018), incubated for 1 hr at 37 °C, washed 5x 100 μl with 
PBS-T (PBS, 0.1% Tween20), and stored at 4 °C. Peptides were synthesized 
using solid phase synthesis and purified to >95% purity.  The well characterized 
Nrp inhibitory peptide ATWLPPR was used as a positive control (Sigma-Genosys, 
St. Louis, MO).  Two dimeric disulfide linked peptides of the C-terminal region of 
Sema3F were synthesized, oxidized to produce the natural intramolecular 
disulfide, and purified (Genscript, Piscataway, NJ).  One peptide, C-Sema, 
corresponds to the final 46 residues of Sema3F 
(GLIHQYCQGYWRHVPPSPREAPGAPRSPEPDQKKPRNRRHHPPDT) while the 
second peptide, C-furSema, is 40 residues and corresponds to the furin cleaved 
species (GLIHQYCQGYWRHVPPSPREA PGAPRSPEPQDQKKPRNRR). Two 
peptide libraries, one in which the C-1 residue of the S3F C-terminus 
(WDQKKPRNXR) was substituted for all twenty amino acids and another that 
corresponded to the last nine residues of all Sema3 family members, were 
synthesized and purified by HPLC, with an average purity of 90% (NEO Group, 
Cambridge, MA). An N-terminal tryptophan was added to aid in quantitation. 
     Peptides were resuspended in binding buffer and combined with AP-VEGF-A 
at peptide concentrations ranging from 500 μM to 230 nM and a final AP-VEGF-A 
activity of 1 μmol of pNPP hydrolyzed/min per μl. The pre-mixed AP-VEGF-
A/peptide solution was then added to Nrp1 affinity plates and incubated for 1 hr at 
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25 °C. Wells were washed with 100 μl of PBS-T three times using an EL404 plate 
washer (BioTek, Winooski, VT) and an additional 100 μl of PBS-T was added to 
the plate and incubated for 5 min. The wash solution was then removed and 100 
μl of 1X alkaline phosphatase substrate was added(Jardin et al., 2008). After 25 
minutes the reaction was quenched by adding 100 μl of 0.5N NaOH and the plate 
was read at 405 nm on a SpectraMax M5 plate reader (Molecular Devices, 
Sunnyvale, CA). Retained AP-VEGF-A binding was plotted against peptide 
concentration to generate an inhibition curve that was fit with a four-parameter 
sigmoidal dose response curve to determine the half-maximal inhibitory 
concentration (IC50). Results are reported for each peptide as the mean IC50 ± 
standard deviation of two independent experiments.   
 For quantitative binding experiments, the absolute concentration of AP-
VEGF-A164 and AP-VEGF-A120 was determined using the quantitative MMV00 
enzyme linked immunosorbent assay (ELISA) (R&D Systems).  Binding of AP-
VEGF-A164 and AP-VEGF-A120 to Nrp1 or Nrp2 was measured as a function of 
retained AP activity.  Binding curves were fit using a one-site specific binding mode 
to determine Kd (Graphpad Prism). Kd error is presented as the 95% confidence 
interval. 
Isothermal titration calorimetry 
Peptides with sequence WDQKKPRNRR (S3F-RR) and WDQKKPRNPR (S3F-
PR) were synthesized by solid-phase synthesis and purified to >95% purity 
(LifeTein, South Plainfield, NJ). Purified Nrp1-b1b2 and the S3F peptides were 
exhaustively dialyzed against ITC buffer (10 mM phosphate, 238 mM NaCl, 2.7 
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mM KCl, pH 7.4). Following dialysis, Nrp1 was concentrated to 40 μM and S3F 
peptides were diluted to 390 μM as measured by OD280 (NanoDrop 1000, Thermo 
Scientific). 
     Binding between Nrp1 and the S3F peptides was measured using a VP-ITC 
Microcalorimeter (MicroCal, GE Healthcare) and data was processed with Origin 
software (OriginLab, Northampton, MA). Nrp1-b1b2 was transferred into the 
sample cell and the syringe was loaded with S3F. Sample measurements were 
made at 30 °C and the system was set to provide a reference power of 10 μcal/sec. 
Thirty 10 μl injections were made, spaced 250 sec. apart. To determine the heat 
of ligand dilution, S3F-RR and S3F-PR were separately injected into ITC buffer 
utilizing the same parameters as the experimental runs. The heat of ligand dilution 
was subtracted from the heat of binding to generate a binding isotherm that was fit 
with a one-site binding model in Origin, allowing determination of the association 
constant (Ka), enthalpy (ΔH), and entropy (ΔS) of the interaction.  Ka was used to 
calculate Kd (Kd=1/Ka). ITC data was collected in quadruplicate for each peptide 
with independent preparations of Nrp1-b1b2. 
Western blot analysis of Sema3F furin processing 
The Ig-basic domains of human Sema3F (residues 605-785, S3F-Hgh), as well as 
the single point mutant, R778P (R778P-Hgh), were cloned into the pLexM vector 
(Aricescu et al., 2006) for expression with an N-terminal PTP-α signal sequence 
and C-terminal Hgh fusion (Leahy et al., 2000). Protein was expressed by transient 
transfection from CHO, furin deficient FD11, and furin overexpressing cells 
(Gordon et al., 1995). Western blot analysis was performed on conditioned 
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medium from all cell types to detect the Ig-basic-Hgh fusion protein (unprocessed) 
or free Hgh (processed) as previously described (Parker et al., 2010). An anti-Hgh 
polyclonal primary antibody (1:10000 dilution, RD1-HGHabrX1, Fitzgerald 
Industries, Acton, MA) and anti-rabbit HRP secondary antibody (1:20000 dilution, 
sC-2301, Santa Cruz Biotechnology, Santa Cruz, CA) were utilized and the blot 
was developed using SuperSignal West Pico (Pierce Biotechnology, Rockford, IL). 
Image Lab software (Bio-Rad Laboratories, Hercules, CA) was used to calculate 
the percent of processed Ig-basic-Hgh relative to total protein. 
 Prism (Graphpad Software, La Jolla, CA) was used for analyzing and 
graphing data and for calculating the statistical significance between sets of data 
as determined by a student’s t-test. Molecular graphics were generated using 
Pymol (The PyMOL Molecular Graphics System, Version 1.5.0.2 Schrödinger, 
LLC). 
AP-VEGF-A Recovery Assay 
To measure the preferential binding of Nrp1 and Nrp2 to Sema3F or VEGF-A the 
potential of Nrp to promote the recovery of C-furSema [19] mediated inhibition of 
AP-VEGF-A binding to Nrp1 was assessed. Nrp1 and Nrp2 were combined with 
both AP-VEGF-A (155 μmole p-NPP hydrolyzed/min/L) and C-furSema3F (45nM, 
the concentration at which ≈90% inhibition is achieved) in incubation buffer and 
added to low density Nrp1 affinity plates for 1hr at 25C. Plates were washed and 
retained AP activity quantitated as described above.  Retained AP-VEGF-A was 
reported versus Nrp concentration as the percent of binding observed relative to 
uninhibited AP-VEGF-A (no C-furSema).  
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Circular Dichroism 
Circular dichroism (CD) spectra were collected using a Jasco J-810 
Spectropolarimeter. Wild-type and chimeric proteins were added to a 0.1-cm-
pathlength cuvette at 10μM in PBS pH 7.4. Spectra were recorded at a speed of 
20nm/min using the average of three accumulations over a range of 205-245 nm. 
Data are reported as per residue molar ellipticity. 
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CHAPTER 3: FURIN PROCESSING OF SEMA3F DETERMINES ITS ANTI-
ANGIOGENIC ACTIVITY BY REGULATING DIRECT BINDING AND 
COMPETITION FOR NRP 
Introduction 
 Vertebrates employ a wide array of secreted growth factors and cell surface 
receptors to regulate the growth and guidance of axons.  The semaphorins 
represent one of the largest families of cytokines that directly guide axon growth 
(Koncina et al., 2007; Zhou et al., 2008).  There are five recognized families of 
semaphorins in vertebrates, including the Sema3 family, all six members of which 
are secreted and able to diffuse through tissues (Kolodkin et al., 1993).  Nrp directly 
binds to most Sema3 family members and is essential for axonal guidance (He 
and Tessier-Lavigne, 1997; Nakamura et al., 1998). 
 Nrp interacts with members of the Sema3 family of ligands and functions 
together with plexin family receptors in Sema3 mediated axon guidance (Fujisawa, 
2004; Takahashi et al., 1999).  Nrp also interacts with the VEGF family of ligands 
and functions together with VEGFR family receptors in VEGF mediated 
angiogenesis (Klagsbrun et al., 2002; Soker et al., 1998).  Higher eukaryotes 
possess two Nrp family members, Nrp1 and Nrp2, which share 44% amino-acid 
sequence identity (Kolodkin et al., 1997).  They both function in Sema3 and VEGF 
signaling but differ in their substrate specificity among ligands and receptors, as 
well as specific control of protein expression and recycling (Chen et al., 1997).  In 
vivo, Sema3F functions via Nrp2 to control axon guidance both in the CNS and 
peripheral nervous system (Sahay et al., 2003). 
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 The coagulation factor domains of Nrp, b1 and b2, contain the high-affinity 
binding site for both VEGF and the C-terminal domain of Sema3 (Giger et al., 1998; 
Mamluk et al., 2002).  Because Sema3 and VEGF share an overlapping binding 
site within the b1 domain of Nrp, the role of Nrp in mediating interplay between the 
two seemingly distinct pathways of VEGF dependent angiogenesis and Sema3 
dependent axon guidance is the source of considerable interest.  However, there 
are conflicting reports as to the role and extent of ligand competition for Nrp 
binding.   
 A number of researchers have observed direct competition between VEGF 
and Sema3 (Gu et al., 2002; Miao et al., 1999; Narazaki and Tosato, 2006).  This 
is consistent with both VEGF and Sema3 families possessing a highly basic C-
terminal domain that interacts with the b1 domain of Nrp.  Additionally, multiple 
Sema3 family members have been shown to have potent anti-angiogenic activity 
in vivo (Adams et al., 1997; Christensen et al., 2005; Kessler et al., 2004). 
 Surprisingly, a number of other researchers have recently reported that 
there is no competition between VEGF and Sema3 (Appleton et al., 2007; Vieira 
et al., 2007).  Previous studies defined the critical importance of a C-terminal 
arginine residue in the binding of both VEGF and inhibitory peptides to Nrp 
(Starzec et al., 2007; Teesalu et al., 2009; Vander Kooi et al., 2007; von Wronski 
et al., 2006).  The observed lack of ligand competition for Nrp is consistent with the 
fact that no Sema3 family members possess a C-terminal arginine, and it has been 
suggested that two distinct surfaces in the b1 domain of Nrp may be employed for 
ligand binding. 
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 These conflicting reports suggest that a critical mechanistic feature of Nrp 
ligand binding is not understood.  This has motivated studies to determine the 
physical mechanism for the interaction of Nrp and Sema3 and the basis for 
Sema3’s observed anti-angiogenic activity.  The immediate C-terminus of Sema3 
is not well conserved and does not contain a C-terminal arginine residue (Figure 
3.1, A).  However, a region just upstream of the C-termini is, in fact, highly 
conserved and has been shown to be a cleavage site for the furin family of pro-
protein convertases.  Proteolytic processing in Sema3’s C-terminal domain has 
been shown to regulate the anti-angiogenic potency of several Sema3s, which has 
been suggested to involve Nrp binding (Adams et al., 1997; Christensen et al., 
2005; Potiron et al., 2009).  We hypothesized that proteolytic activation of the C-
terminus of Sema3 may be critical for regulating interaction with Nrp.  We 
demonstrate that Sema3F is proteolytically processed at its C-terminus.  This 
processing is essential for the production of a mature C-terminal region of Sema3F 
that can physically interact with Nrp.  Further, the mature form of Sema3 potently 
blocks VEGF binding to Nrp.  These data demonstrate that mature Sema3 and 
VEGF ligands do compete for binding to the overlapping binding site in the b1 
domain of Nrp, but that furin processing of Sema3 is essential for its physical 
interaction and anti-angiogenic potency.  These findings resolve conflicting results 
in the literature by providing a physical basis for understanding the regulation of 
Sema3 interaction with Nrp.  Further, these results open new avenues to 
understand the cross-talk between neuronal and vascular guidance through ligand 
competition for a shared co-receptor. 
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Results 
Sema3F is proteolytically processed in its C-terminal domain 
 Sema3F possesses an RXRR consensus furin-like protease recognition 
sequence at its C-terminus.  This region is highly conserved in five of the Sema3 
family members (Figure 3.1, A).  To test whether Sema3F is proteolytically 
processed in its C-terminus, we expressed the C-terminal Nrp binding region of 
Sema3F (Ig-basic) with a C-terminal human growth hormone (Hgh) fusion. The 
construct was expressed in CHO cells, FD11 CHO cells lacking furin activity, and 
CHO cells overexpressing furin (Gordon et al., 1995).  Wild-type CHO cells 
expressed a mixture of processed and unprocessed forms of Sema3F (Figure 3.1, 
B).  FD11 cells produced solely the unprocessed form of Sema3F, whereas furin 
overexpressing cells produced only the processed form (Figure 3.1, B).  To further 
confirm that the observed proteolytic processing is the result of furin activity, the 
construct was expressed in COS-7 cells.  The protein was found to be >95% 
processed (Figure 3.1, C).  The observed proteolytic processing is fully blocked by 
addition of furin inhibitors (Figure 3.1, C). Thus, as has been previously observed 
with other Sema3 family members (Adams et al., 1997; Christensen et al., 2005), 
Sema3F is proteolytically processed in its C-terminal basic domain. 
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Figure 3.1:  Furin processing of Sema3F.  
A) Sema3 family members contain a conserved furin recognition sequence in their 
C-terminus.  B) A mixture of unprocessed (100 kDa) and processed (24 kDa) forms 
of Sema3F-Hgh fusion are observed when overexpressed in CHO cells.  Furin 
deficient (FD11) cells produce only the unprocessed form, whereas furin 
overexpressing cells produce only the processed form.  C) Sema3F-Hgh 
expressed in COS-7 cells is nearly completely processed, whereas addition of furin 
inhibitors produces almost complete reversal to the unprocessed form.  Protein 
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molecular weights were estimated using the Magic Mark XP molecular weight 
standard (MW) (Invitrogen, Carlsbad, CA).  
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C-terminal processing of Sema3F regulates interaction with Nrp  
  A specific interaction has been shown between the C-terminus of Sema3F 
and core ligand binding domains (b1b2) of Nrp2 (Giger et al., 1998).  To determine 
the effect of the observed proteolytic processing, we tested the ability of the 
unprocessed and processed forms of Sema3F to interact with Nrp, utilizing a Nrp2 
affinity pull-down of the C-terminus of Sema3F.  In order to test the effect of the C-
terminal sequence, a construct was produced with a native C-terminal sequence 
and the Hgh attached to the N-terminus.  Furin cleavage would remove only six 
residues at the C-terminus and so, as expected, no difference in apparent 
molecular weight is observed between N-terminally tagged protein expressed in 
Cos-7 cells in the absence or presence of furin inhibitors.  However, a dramatic 
difference is observed in their ability to interact with Nrp2.  The processed form of 
Sema3F, expressed from COS-7 cells in the absence of furin inhibitors, shows a 
robust interaction with the Nrp2 affinity resin (Figure 3.2, A).  This result is 
consistent with previous reports describing the domain specific interaction 
between the C-terminal Ig-basic domain of Sema3F and Nrp2 (Giger et al., 1998).  
In contrast, the unprocessed form, expressed from Cos-7 cells in the presence of 
furin inhibitors, shows little if any ability to interact with the Nrp2 affinity resin 
(Figure 3.2, A).  This result suggests that the mechanism underlying the profound 
physiological effect of furin processing of Sema3 may be direct regulation of the 
physical interaction between the C-terminus of Sema3 and the b1 domain of Nrp. 
 To more fully characterize the interaction of the C-terminus of Sema3 with 
Nrp, we produced peptides from the C-terminus of Sema3F that include the C-
 39 
terminal intermolecular disulfide and basic domain.  This allowed production of a 
pure, chemically defined species corresponding to the unprocessed (C-Sema, the 
final 46 residues of Sema3F) and processed (C-furSema, the same with the final 
six residues removed, thus possessing a C-terminal arginine) forms of Sema3F.   
 To quantitatively characterize the interaction of the two proteins, the binding 
of FITC labeled C-furSema to Nrp2 was measured using fluorescence anisotropy.  
Incubation with Nrp2 resulted in a significant increase in anisotropy consistent with 
a decrease in the rotational diffusion of the bound complex.  The observed binding 
was well fit with a single site binding model (R2=0.99) and allowed determination 
of the dissociation constant Kd=4.1±0.5 mM (Figure 3.2, B). 
 Based on these data, we conclude that furin mediated activation of Sema3F 
is critical for the physical interaction of the C-terminus of Sema3F with Nrp2. This 
likely represents an important regulatory mechanism since the furin family of pro-
protein convertases is differentially expressed in the developing brain (Zheng et 
al., 1994), suggesting that processing of Sema3 is spatially regulated. 
Binding of C-furSema to Nrp1  
 Sema3F functions with Nrp2 in axon guidance, but functionally blocks 
VEGF-A binding to Nrp1 to block angiogenesis.  To determine the basis for 
Sema3F anti-angiogenic activity, we first tested if C-furSema was also able to bind 
to Nrp1.  The binding of FITC C-furSema to Nrp1 was determined using 
fluorescence anisotropy as with Nrp2.  Binding was again well fit with a single site 
binding model (R2=0.99) and a dissociation constant Kd=2.2±0.2 μM (Figure 3.2, 
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C).  Thus, C-furSema can bind both to Nrp2 and Nrp1, the latter with slightly higher 
affinity.   
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Figure 3.2: Interaction of the C-terminus of Sema3F with Nrp2 and Nrp1. 
A) Affinity purification of the Hgh-Sema3F C-terminus using Nrp2 affinity resin 
demonstrates that only the protein with a furin processed C-terminus is efficiently 
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pulled down.  B) FITC C-furSema shows a significant increase in anisotropy when 
bound to Nrp2, which is fit well with a single site binding curve.  C) Nrp1 also binds 
to FITC C-furSema with slightly higher affinity. 
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Inhibition of VEGF binding   
 To test whether the observed anti-angiogenic activity of Sema3F is due to 
direct competition with VEGF-A for binding to Nrp1, we developed a novel 
inhibitory assay.  This assay measures the ability of Sema3F to compete with 
VEGF-A for binding to the core ligand binding domains (b1b2) of Nrp1.  Nrp1 was 
adsorbed to 96-well plates to which AP-tagged VEGF-A binds specifically. VEGF-
A binding could be competitively blocked using anti-angiogenic inhibitory peptides 
or other blocking reagents.  Bound AP-VEGF-A was quantitatively determined 
using a colorometric p-NPP based assay (Figure 3.3, A).   
 C-furSema, representing the processed form of Sema3F, was able to fully 
inhibit the binding of AP-VEGF-A to Nrp.  C-furSema was found to be a very potent 
inhibitor with an IC50=46 ± 3 nM (R2=0.9999) (Figure 3.3, B, green).  This 
demonstrates that, in fact, Sema3F and VEGF-A do directly compete for binding 
to the core ligand binding domains of Nrp, explaining the anti-angiogenic potency 
of Sema3F in vivo. 
 To determine the effect of proteolytic activation of Sema3F on anti-
angiogenic potency, we tested the ability of C-Sema to competitively block VEGF-
A binding to Nrp.  C-Sema, representing the unprocessed form of Sema3F, 
showed no inhibition of VEGF-A binding even at high concentrations (Figure 3.4, 
B, red). 
 These results underline the essential importance of furin processing of 
Sema3, and provide a mechanism for the observed anti-angiogenic potency of 
Sema3F.  In summary, we demonstrate that furin processing produces a form of 
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Sema3F that binds to the core ligand binding domains of Nrp and directly 
competes with VEGF-A for receptor binding. Since processing occurs within the 
Sema3F basic domain, proteolysis may also regulate Sema3’s ability to interact 
with the ECM, such as is seen for VEGF-A. Indeed, specific glycosaminoglycans, 
components of the ECM, have been shown to interact with Sema3, VEGF, and 
Nrp and are known to be important mediators of angiogenesis and neuronal axon 
guidance (Dick et al., 2013; Stringer, 2006; Vander Kooi et al., 2007). 
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Figure 3.3:  C-furSema potently inhibits VEGF-A binding to Nrp.   
A) Design of a novel plate based inhibition assay measuring the displacement of 
AP-tagged VEGF-A from Nrp1 b1b2 coated plates with increasing concentration 
of peptide. B) C-furSema potently inhibits the binding of AP-VEGF-A to Nrp1 with 
an IC50=45nM (green).  C-Sema shows no inhibitor potency even at high 
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concentrations (red).  Each point is the average of three independent samples with 
error bars representing +/- one standard deviation. 
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Discussion 
 We demonstrate that Sema3F is proteolytically processed at its C-terminus. 
This processing is essential for the interaction of Sema3F with the core ligand 
binding domains of Nrp.  Our data provides a physical explanation for this, since 
furin processing liberates a C-terminal arginine.  Possession of a C-terminal 
arginine has been demonstrated to be critical for the interaction of both VEGF and 
peptide inhibitors with Nrp (Starzec et al., 2007; Vander Kooi et al., 2007).  Further, 
the b1 domain of Nrp is utilized for binding both VEGF and Sema3 families of Nrp 
ligands, yet the nature of the different ligand interactions with and competition for 
Nrp has been unclear.  We demonstrate that the two classes of ligands directly 
compete for Nrp binding, but only when Sema3 is processed.  A C-terminal peptide 
representing the proteolytically processed form of Sema3F potently blocks the 
binding of VEGF to Nrp, explaining the anti-angiogenic activity of Sema3F (Figure 
3.4).   
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Figure 3.4: Model for the mechanism of anti-angiogenic activity of Sema3F.   
Our data demonstrates that furin dependent activation of the C-terminus of 
Sema3F is essential for direct interaction with Nrp and anti-angiogenic activity via 
competition with VEGF-A for binding to the b1 domain of Nrp. 
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 Understanding the mechanistic basis for the interaction of the C-terminus 
of Sema3 with Nrp also provides a simple yet elegant explanation for the divergent 
literature reports regarding the competition of VEGF and Sema3 ligands for Nrp 
binding.  C-terminal fusions, such as Fc or AP, are often used in the expression 
and purification of Sema3 family members.  This includes commercially available 
Sema3s, which are expressed and purified using a C-terminal Fc-fusion (R & D 
Systems).  These proteins represent solely the unprocessed form of Sema3 and, 
as expected from our studies, are unable or have dramatically decreased ability to 
compete with VEGF for binding to Nrp. When using a C-terminal tag, such as AP, 
for quantitation but not purification, the protein produced will likely be a mixture of 
the processed and unprocessed forms.  When using an N-terminal tag, care should 
be taken since proteolytic processing of the C-terminus does not produce an 
appreciable shift in molecular weight and thus a mixture of processed forms will be 
produced unless furin activity is specifically inhibited or enhanced.  It is interesting 
to note that Sema3F produced in wild-type CHO cells has a larger percentage of 
unprocessed protein, whereas that produced in COS-7 cells is almost completely 
processed.  In vitro, the ratio of processed to unprocessed Sema3 will be highly 
dependent on the cell type used to express the protein.  In vivo, cell and tissue-
specific proteolytic processing of Sema3 family members may well represent an 
important mechanism controlling the production of anti-angiogenic Sema3s. 
 The role of proteolytic processing of the C-terminus of Sema3F is the 
simplest case for the Sema3 family, since it possesses a single furin consensus 
site in its C-terminus.  Other family members have additional furin-like consensus 
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sites.  For instance, it has been demonstrated experimentally that Sema3A can be 
processed at three different sites in its final forty-five residues (Adams et al., 1997).  
It will be interesting to determine if proteolytic processing at these different sites 
produces proteins with differing anti-angiogenic potency. 
 Paradoxically, it has been shown that furin processing of Sema3B can 
inactivate its anti-angiogenic potency (Varshavsky et al., 2008).  However, the 
observed cleavage is at a known site in the middle of the Sema3 gene, upstream 
of the Ig domain, and removes the entire Ig-basic region, including the cysteine 
that forms the critical intermolecular disulfide essential for Sema3 function 
(Kolodkin et al., 1993).  Thus, proteolytic processing of Sema3 can either activate 
or inactivate its anti-angiogenic potency, depending on the site of proteolysis.   
 The difference between the observed direct binding affinity of C-furSema to 
Nrp and its inhibitory potency in blocking VEGF binding to Nrp is of interest.  The 
observed binding affinity of C-furSema for Nrp (2.2 mM) is comparable to those 
reported for VEGF binding to Nrp1 (2 mM) by surface plasmon resonance with low 
Nrp density (Fuh et al., 2000). However, VEGF binding to Nrp has been shown to 
be highly dependent on Nrp density, with four fold higher density of Nrp leading to 
a twenty-fold increase in apparent affinity (Fuh et al., 2000).  The higher potency 
of inhibition observed in our plate-based inhibitory assay is consistent with this 
result, since maximal amounts of Nrp are coupled to the plate.  C-furSema’s 
inhibitory potency in the plate based assay is thus likely due to avidity affects of 
the dimeric ligand binding to two Nrp molecules, and accurately reproduces the 
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inhibitory potency of previously reported peptides measured both in vitro and in 
situ.   
 These data establish Sema3 C-terminal proteolysis as an essential 
mechanism regulating Sema3 binding to the Nrp coagulation factor domains. 
Interestingly, C-terminal proteolysis across the Sema3 family is predicted to 
generate ligands with divergent C-terminal sequence. Thus, one exciting area for 
future research is aimed at determining whether furin proteolysis can liberate 
specific sequence elements upstream of the non-variant C-terminal arginine as a 
mechanism to modulate Sema3/Nrp affinity.  
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CHAPTER 4: EFFECT OF C-TERMINAL SEQUENCE ON COMPETITIVE 
SEMA3 BINDING TO NRP1 
Introduction 
 The Nrp family of type I transmembrane receptors coordinate critical 
signaling events in the cardiovascular and nervous system where they are 
essential in development, homeostasis, and pathogenesis. The two families of 
canonical Nrp ligands are the VEGF family of pro-angiogenic cytokines and the 
Sema3 family of axon guidance molecules (rev. in (Parker et al., 2012a)). VEGF 
signaling via Nrp and a VEGFR receptor tyrosine kinase family member is 
essential for physiological and pathological angiogenesis and plays a causative 
role in tumorigenesis (rev. in (Carmeliet, 2005; Ellis, 2006)) and wet macular 
degeneration (Cui et al., 2003; Rosenfeld et al., 2006). Additionally, it has recently 
been shown that Nrp is critical for autocrine cancer stem cell activation and 
maintenance (Beck et al., 2011; Goel et al., 2013). Sema3 signaling via Nrp and 
Plexin receptors mediates physiological axon guidance and contributes to 
pathological axon repulsion following CNS injury (rev. in (Hota and Buck, 2012; 
Niclou et al., 2006)). 
 Because of its role in multiple pathological conditions, Nrp represents an 
attractive therapeutic target. Peptides (Parker et al., 2010; Starzec et al., 2006; 
von Wronski et al., 2006), peptidomimetics (Jarvis et al., 2010), soluble receptor 
fragments (Gagnon et al., 2000), and monoclonal antibodies (Appleton et al., 2007; 
Liang et al., 2007; Pan et al., 2007a) have all been explored as Nrp binding and 
blocking molecules.  Peptides are the best-studied class of Nrp targeting and 
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modulating molecules and have been developed not only for their competitive 
ligand binding activity but also for other diverse purposes including in vivo Nrp 
diagnostic imaging (Benachour et al., 2012; Perret et al., 2004) and for cargo 
targeting to Nrp-expressing tumors (Roth et al., 2012; Teesalu et al., 2009). Nrp 
ligand-blocking peptides include sequences derived from endogenous Nrp ligands 
(Jia et al., 2006; Parker et al., 2010), the naturally occurring immunostimulatory 
peptide Tuftsin (von Wronski et al., 2006), and phage-display derived peptides 
(Starzec et al., 2006; Teesalu et al., 2009). Initial mechanistic and developmental 
work has provided critical insights into Nrp ligand binding, but additional insights 
are needed to produce peptides that are optimized for potency, selectivity, and 
stability.  
 Biochemical and structural approaches have demonstrated that all known 
Nrp ligands require a C-terminal arginine (CR) for binding to a conserved pocket in 
the Nrp b1 domain (Delcombel et al., 2013; Parker et al., 2010; Parker et al., 2012c; 
Vander Kooi et al., 2007).  Alternative splicing generates a CR in many VEGF 
families, including VEGF-A (rev. in (Harper and Bates, 2008)) and VEGF-B 
(Olofsson et al., 1996b), but proteolytic maturation is required in the case of VEGF-
C and VEGF-D (Karpanen et al., 2006). Similarly, Sema3 family members require 
proteolytic activation by furin-family proteases to liberate a CR (Adams et al., 1997; 
Christensen et al., 2005; Varshavsky et al., 2008) that then allows them to function 
as endogenous competitive inhibitors of Nrp, as demonstrated in Chapter 3 (Gu et 
al., 2002; Miao et al., 1999; Parker et al., 2010).  Indeed, relative levels of VEGF 
and Sema3 family members have been shown to critically contribute to 
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tumorigenesis (Bender and Mac Gabhann, 2013; Serini et al., 2013).  Furin family 
proteases cleave substrates following an arginine residue (Hosaka et al., 1991).  
There are between one and three canonical RXXR furin cleavage sites in the C-
terminal basic domain of Sema3 family members, producing Sema3 ligands with 
alternative forms of the C-terminal domain (Adams et al., 1997).   
 All known peptide inhibitors of Nrp also contain a CR and target the 
conserved Nrp-b1 pocket, binding in a mode analogous to that of Nrp ligands (Jia 
et al., 2006; Starzec et al., 2007; Teesalu et al., 2009).  Recently, the structural 
basis for CR dependent Nrp binding has been described. Crystal structures of the 
VEGF-A heparin binding domain (HBD) (Parker et al., 2012c) and Tuftsin (Vander 
Kooi et al., 2007) in complex with Nrp1 revealed a shared mode of receptor 
engagement and have provided critical insight into the physical basis for Nrp 
binding. Two residues of the ligand contribute to Nrp-b1 binding. The CR is critical 
for Nrp binding and mediates the majority of the interface via divalent engagement 
of both the CR side chain and carboxylate at the C-terminus (Parker et al., 2012c). 
The third-to-last residue (denoted as residue-“C-2” hereafter) mediates the other 
interaction, with the C-2 backbone carbonyl forming a hydrogen bond with the 
aromatic hydroxyl of Nrp1-Y297. This interaction is also critical since mutation of 
Y297 results in loss of ligand binding (Herzog et al., 2011). That this interaction 
critically depends on a backbone hydrogen bond is supported by the observation 
that for ATWLPPR, Nrp binding is C-2 sequence-independent but truncation 
smaller than a tetrapeptide eliminated activity (Starzec et al., 2007).  While a CR 
residue is critical for all peptide inhibitors of Nrp, no upstream consensus has been 
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identified. This led us to investigate the sequence-dependence for Nrp-ligand 
binding and inhibition. 
 To determine the role of residues upstream of the CR, we studied the 
sequence dependence of Nrp binding and inhibition of Sema3F derived peptides.  
We found that the C-1 residue serves the critical role of positioning the CR and C-
2 residues to allow concurrent Nrp binding.  A peptide library with substitution of 
all 20 natural amino acids at the C-1 position revealed that residues that naturally 
adopt an extended conformation enhance inhibitory potency by six-fold. A C-1 
proline produced the most potent Nrp binding peptide, which we demonstrate is 
due to a specific reduction in the entropic cost of binding. We further demonstrate 
that there is an inverse relationship between furin processing of Sema3 and 
inhibitory potency across the Sema3 family.  These data provide critical insight into 
the mechanism of Nrp ligand binding and potent inhibition, and describe a novel 
mechanism for regulated Sema3 furin processing and Nrp receptor engagement.  
Results 
C-1 sequence variation critically affects peptide potency 
 To determine the contribution of the C-1 residue to Nrp binding and 
inhibitory potency, a peptide library derived from the C-terminal domain of Sema3F 
(WDQKKPRNRR) was synthesized with all twenty natural amino acids substituted 
at the C-1 position. The library was tested for the ability to inhibit alkaline 
phosphatase (AP)-tagged VEGF-A binding to Nrp1 utilizing an in vitro plate-binding 
assay. Retained AP-VEGF-A was measured as a function of peptide 
concentration. For all peptides, full AP-VEGF-A inhibition was achieved and the 
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concentration of peptide resulting in half AP-VEGF-A inhibition (IC50) was 
determined.  Significant differences in inhibitory potency were observed, with wild 
type Sema3F (S3F-RR, black line, IC50 = 11 μM) showing intermediate potency 
between the peptides with maximum and minimum potency, C-1 proline (S3F-PR, 
green line, IC50 = 4.7 μM) and C-1 aspartate (S3F-DR, red line, IC50 = 28 μM) 
peptides, respectively (Figure 4.1, A).   
 Sequence alteration at the C-1 residue resulted in a significant variation in 
peptide potency (Figure 4.1, B), indicating that this position plays a significant role 
in modulating Nrp binding.  The most potent inhibitor was the C-1 proline peptide, 
which was six times more potent than the aspartate variant. Analysis of previously 
published peptide inhibitors reveals a preference for proline at the C-1 position. 
Modified Tuftsin (TKPPR) and the phage display derived peptide ATWLPPR 
possess a C-1 proline. The prototypic CendR peptide identified by phage display, 
RPARPAR, does not have this sequence element. However, an analysis of the 
other CendR peptides that were initially identified reveals that 30% of all peptides 
contained a C-1 proline, in striking contrast to the 5% theoretical representation if 
there were no selective pressure at the C-1 position (Haspel et al., 2011). 
Collectively these data reveal a significant role for the C-1 position in determining 
competitive binding to Nrp. 
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Figure 4.1: Inhibitory potency of C-1 peptide variants.  
(A) Peptides were titrated to determine their inhibitory potency versus AP-VEGF-
A. Shown are representative inhibition curves for wild type peptide (S3F-RR, black 
line) and the variants with maximum and minimum potency, S3F-PR (green line) 
and S3F-DR (red line), respectively. (B) Table of all C-1 variants with their 
respective IC50. Values are reported as the mean ± standard deviation   
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Potency is correlated with the propensity of the C-1 residue to adopt an 
extended conformation 
 Intriguingly, the identity and chemical properties of the C-1 residue, 
including charge and hydrophobicity, seemed to have little systematic impact on 
potency.  Structural analysis indicates that the C-1 side-chain is dynamic and 
shows little if any direct interaction with Nrp.  Instead, we hypothesized that the C-
1 residue critically tethers the C-2/Nrp1-Y297 hydrogen bond with the CR mediated 
salt-bridge and hydrogen bond network. Using structures of Nrp1 complexes, we 
measured the backbone torsion angles of the C-1 Tuftsin (PDB=2ORZ) and VEGF-
A (PDB=4DEQ) residue to determine whether a specific orientation is required to 
tether the adjacent CR and C-2 interaction interfaces. Although VEGF-A contains 
a C-1 arginine and Tuftsin a C-1 proline, residues with markedly different 
physiochemical properties, their backbone conformations were very similar (Figure 
4.2, A). Analysis of the backbone dihedral angles demonstrate that they lie within 
the extended region of the Ramachandran plot with Φ,Ψ=-89°,108° and -85°,158°, 
respectively (Figure 4.2, B). 
 The extended conformation seen for both proline and arginine indicates that 
residues with an inherent propensity to adopt an extended conformation could, 
when present at the C-1 position, enhance Nrp binding. Upon analysis of all 
variants, it was striking to observe that proline and β-branched amino acids 
(isoleucine, valine and threonine) produced the most potent C-1 variants (Figure 
4.1, B).  We examined the relationship between the IC50 for each C-1 variant and 
the Chou-Fasman β-sheet propensity scale for each amino acid (Fasman, 1989) 
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to determine whether these properties are correlated (Figure 4.2, C). Indeed, 
potency and β-sheet propensity showed a highly significant correlation (correlation 
coefficient (r) = -0.74, p = 0.0003). These data support a correlation between 
competitive potency and preferred C-1 backbone conformation. 
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Figure 4.2: The C-1 residue of Nrp1 ligands adopts an extended backbone 
conformation.  
(A) Superimposition of the product bound structures of VEGF-A (green) 
(PDB=4DEQ) and Tuftsin (gold) (PDB=2ORZ) in complex with Nrp1 (PDB=2ORZ). 
There are two distinct interaction interfaces, one of which is mediated by the CR 
and the other by the C-2 carbonyl of the ligand. The C-1 residue serves the critical 
role of tethering the adjacent interacting residues and correctly orienting them with 
respect to one another within the binding pocket. (B) Ramachandran plot of the Φ 
and Ψ angles of the C-1 VEGF-A (C-1 R) and Tuftsin (C-1 P) residue reveals that 
they adopt an extended conformation. (C) Plotting the IC50 for each C-1 variant 
against the β-sheet propensity of each amino acid reveals a correlation between 
potency and the inherent preference of amino acids to adopt an extended 
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conformation. Proline was excluded from the fit due to its inability to conform to the 
backbone hydrogen bonding pattern present in β-sheets and, therefore, its low β-
sheet propensity.  
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Preferential backbone conformation minimizes the entropic cost 
associated with binding 
 Thus, we hypothesized that peptides with a C-1 residue that inherently 
favors an extended conformation would have increased potency due to decreased 
entropic cost associated with Nrp1 binding.  Therefore, we measured the 
thermodynamic parameters of S3F-RR (WDQKKPRNRR) and S3F-PR 
(WDQKKPRNPR) binding to Nrp1 using isothermal titration calorimetry (ITC).  
 With Nrp1 in the sample cell, peptides were titrated to saturation and the 
resulting binding isotherms were fit with a one-site binding model, allowing 
determination of thermodynamic binding parameters.  S3F-RR (Figure 4.3, A) and 
S3F-PR (Figure 4.3, B) fit to a 1:1 stoichiometry, consistent with a single CR ligand 
binding to monomeric Nrp1. S3F-RR bound to Nrp1 with a Ka=3.0 x 104 M-1 (Kd = 
33 μM) and S3F-PR bound with significantly higher affinity, with a Ka=10.1 x 104 
M-1 (Kd = 10 μM).  The binding enhancement for S3F-PR relative to S3F-RR is 
consistent between direct binding and inhibitor potency (3.0-fold and 2.3-fold, 
respectively). Binding of the less potent wild-type S3F-RR was actually more 
favorable enthalpically (ΔH = -18.5 and -17.0 kcal/mole, for S3F-RR and S3F-PR, 
respectively, p = 0.04).  However, there was a significantly larger loss of entropy 
upon S3F-RR binding as compared to S3F-PR binding (TΔS = -12.2 and -10.0 
kcal/mole for S3F-RR and S3F-PR, respectively, p = 0.009). Thus, the difference 
in entropy accounts for the preferential binding potency of S3F-PR.  
 The measured thermodynamic parameters of binding represent the 
combined changes for both Nrp1 and the peptide upon binding.  No significant 
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differences in the orientation of the bound product in the Nrp b1 binding site (Figure 
4.2, A), conformation of the Nrp1 binding pocket itself (R.M.S.D. = 0.6Å for C over 
residue range 274-429), or protonation state have been indicated. Thus, the 
difference in entropy between S3F-RR and S3F-PR binding can be best 
interpreted in terms of conformational bias in the free ligand. Indeed, it was recently 
suggested that peptide backbone rigidity is able to enhance Nrp binding (Zanuy et 
al., 2013). These data directly support the hypothesis that proline substitution at 
the C-1 position enhances Nrp binding by preferentially positioning the free peptide 
backbone in a ligand bound-like extended conformation that allows engagement 
of the C-2 and CR interactions. With proline at the C-1 position the backbone is 
pre-organized for optimal receptor engagement. 
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Figure 4.3: Analysis of peptide binding by ITC.  
Using ITC the thermodynamic parameters of Nrp1 binding were measured for wild 
type peptide (S3F-RR, A) and the C-1 proline variant (S3F-PR, B). A 
representative binding isotherm is shown for each peptide. Values are reported as 
the mean ± standard deviation of four independent experiments. 
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Arginine is conserved at the C-1 position in Sema3F to maintain efficient 
proteolytic maturation 
 Although a C-1 proline residue confers an advantage for Nrp1 binding, the 
majority of furin consensus sequences present in Sema3 family members possess 
a C-1 arginine residue. This opens the question of why arginine, as opposed to 
proline, is preferred at the C-1 position of Sema3 family members. The Sema3 
family of ligands require processing by furin family proteases for biological 
function(Adams et al., 1997). This processing event liberates a CR and is required 
for Nrp1 binding (Parker et al., 2010). We hypothesized that the C-1 residue may 
directly affect furin-dependent proteolysis.  
 To test this hypothesis, we expressed the Sema3F Ig-basic domains with a 
C-terminal human growth hormone (Hgh) fusion as either the wild type sequence 
(S3F-Hgh) or with the C-1 residue mutated to proline (R778P-Hgh) (Figure 4.4, A). 
S3F-Hgh and R778P-Hgh were secreted at similar levels, but processing by furin 
was significantly different (Figure 4.4, B). When expressed in wild type CHO cells, 
over 40% of S3F-Hgh protein was cleaved but only 10% of R778P-Hgh could be 
processed.  No processing was observed for either S3F-Hgh or R778P-Hgh when 
expressed in CHO cells deficient in furin activity (FD11) (Gordon et al., 1995), 
demonstrating that the observed processing is due to furin activity. In contrast, in 
CHO cells stably overexpressing furin (Gordon et al., 1995), the majority (70%) of 
secreted S3F-Hgh was furin processed, while 30% of R778P-Hgh was processed.  
These data demonstrate that a C-terminal di-arginine motif allows optimal 
proteolysis by furin family proteases and that variation at the C-1 position alters 
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proteolytic efficiency.  It is notable that R778P-Hgh is partially processed and that 
this processing increases in cells with higher levels of furin activity.  Thus, tissue 
specific differences in furin activity or differential expression of different proprotein 
convertase (PPC) family members may serve as a regulatory mechanism 
underlying activating proteolysis of the different furin sites.  
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Figure 4.4: Mutation of the Sema3F C-1 residue alters processing 
efficiency.  
(A) The Ig-basic domains of Sema3F were expressed as a C-terminal Hgh fusion. 
In addition to wild type protein (S3F-Hgh), a mutant with the C-1 arginine residue 
of the furin consensus site mutated to proline (R778P-Hgh) was expressed. The 
arrow indicates the site of furin proteolysis. (B) S3F-Hgh and R778P-Hgh were 
expressed in CHO, furin deficient (FD11), and furin over expressing (Furin) cells 
and the efficiency of processing was measured by blotting for Hgh. S3F-Hgh was 
processed in CHO and Furin cells, as detected by the presence of the processed 
form, but significantly less processing was seen for R778P-Hgh in these cell types. 
Neither construct was processed in FD11 cells. 
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C-1 variation in the Sema3 family alters Nrp1 binding 
 Sema3F contains a single furin proteolysis site in its C-terminus.  This site 
has a strong furin consensus (KXRXRR) and is conserved in five of the seven 
Sema3 family members (Figure 4.5, A, site 2). While it is clear that this extended 
basic sequence serves as an ideal furin substrate, different Sema3 family 
members possess up to two other furin sites that have a conserved dibasic RXXR 
motif (Molloy et al., 1992; Watanabe et al., 1993) and have been demonstrated to 
be processed (Adams et al., 1997; Christensen et al., 2005; Varshavsky et al., 
2008). For all family members, cleavage at the first and second furin site results in 
a C-1 arginine, while processing at the third site results in a C-1 P residue (Figure 
4.5, B). By aligning the terminal four amino acids of all Sema3 family members, 
the differential usage of arginine and proline at the C-1 position is clearly illustrated 
(Figure 4.5, C) indicating two distinct classes of furin cleavage sites.  
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Figure 4.5: Furin proteolysis of Sema3 generates divergent C-terminal 
sequences.  
(A) The Sema3 family of ligands are furin processed at multiple sites within their 
C-terminus that result in either a C-terminal arginine-arginine motif (site 1 and 2) 
or a proline-arginine motif (site 3). (B) Peptides corresponding to all furin cleavage 
sites (black arrow) within the basic domain of Sema3 family members were 
synthesized with a leading tryptophan (grey). Sema3 variants are labeled 
according to family member (A-G) and cleavage site number (1-3). (C) An 
alignment of the four C-terminal residues of all Sema3 peptides illustrating the 
either-or preference for proline and arginine at the C-1 position. The height of the 
amino acids at each position represents their relative conservation within the 
alignment. 
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 We tested the VEGF inhibitory potency of peptides representing all forms 
of each member of the Sema3 family and found very significant differences.  
Greater than a 40-fold difference was observed between the different Sema3 
family members and an 18-fold difference between different sites in the same 
Sema3 family member (Sema3A) (Figure 4.6, A). Sema3E.3 was the most potent 
inhibitor with an IC50 = 0.76 μM and Sema3A.2 was the weakest inhibitor with an 
IC50 = 34 μM. Notably, all peptides with a C-1 proline were more potent than all 
peptides with a C-1 arginine (Figure 4.6, A). Indeed, when grouped by their C-1 
residue (Figure 4.6, B), peptides with a C-1 arginine had a mean potency of 19 ± 
11 μM, as opposed to peptides with a C-1 proline that had a mean potency of 2.4 
± 1.4 μM (p = 0.02). Otherwise, no correlation between potency and sequence, 
equivalent to that for the C-1 residue, was observed at other upstream positions.  
This does not rule out additional secondary effects, since a range of IC50 values 
are observed within the two C-1 groups.  For instance, it is interesting to note that 
furin processing at site 2, the most conserved in the Sema3 family, always 
produces a C-2 asparagine (Figure 4.5, B), and these peptides showed the 
weakest VEGF inhibitory potency (Figure 4.6, A). A strongly negative preference 
for aspartate/asparagine is observed in the C-1 position (Figure 4.2, C), and it may 
be that the sidechain of an asparagine residue in either the C-1 or C-2 position 
competes with Nrp for mainchain interactions, thereby lowering affinity.   
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Figure 4.6: Sema3 family variation in potency is explained by the C-1 amino 
acid.  
(A) The ability of all Sema3 ligand variants to inhibit VEGF-A binding to Nrp1 was 
measured. The data are reported as the mean IC50 ± standard deviation. (B) The 
IC50 for each peptide was plotted against the amino acid present at the C-1 
position. Peptides with a C-1 proline (average IC50 = 2.4 ± 1.4 μM) were 
significantly more potent than those with a C-1 arginine (average IC50 = 19 ± 11 
μM). (C) The C-1 residue inversely effects furin consensus strength and Nrp 
affinity.   
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Discussion 
 Cumulatively, these data demonstrate that there is an inverse relationship 
between furin processing and Nrp binding. While a C-1 arginine is best suited for 
furin processing, a C-1 proline is best suited for Nrp1 engagement. Intriguingly, 
while the majority of furin sites in the different Sema3 family members have a C-1 
arginine, those without an arginine exclusively possess a proline residue at this 
position, suggesting a possible tissue-specific regulatory mechanism of Sema3 
activity. 
 While furin processing is critical, a differential physiological role and how 
processing at the distinct sites is regulated is currently unknown.  These data 
indicate that there are two physically distinct classes of non-equivalent furin sites 
in the C-terminal domain of Sema3 family members that are differentiated by their 
C-1 residue. Indeed, it has been demonstrated within the context of full-length 
protein that Sema3A cleaved solely at site 3 (Sema3A.3) shows maximal potency 
and that when processing at this site is abolished, function is markedly reduced in 
situ (Adams et al., 1997). Additionally, conformational flexibility may be important 
for productive assembly of the Sema3 signaling complex, as suggested by the 
recent structural characterization of the Nrp1/Sema3A/PlexinA2 complex (Janssen 
et al., 2012). Differential furin processing could modulate the interdomain distance 
between the Sema3 sema domain and basic domain CR, which engage Nrp a1 
and b1 domains, respectively (Parker et al., 2012a; Parker et al., 2012b). It is 
interesting to note that Sema3A.3 is the most potent sequence as well as the most 
C-terminal furin site opening the possibility for coupling between binding site 
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sequence and spacing.  Thus, in physiological context, processing at the different 
sites can produce different amplitude of Sema3 signaling, thereby providing a 
mechanism for control of Sema3 signaling by regulation of both expression and 
selective processing. 
 These data demonstrate that the C-1 position of Nrp binding peptides and 
ligands is critical for regulating both potency and processing. This provides insight 
into the mechanism of potent Nrp-binding and inhibition and lays the groundwork 
for continued improvements to the potency and specificity of peptide inhibitors of 
Nrp.  Further, by studying the C-1 residue in the context of the C-terminus of 
Sema3 we have gained an understanding of physiological Sema3 ligand function. 
Interestingly, the Sema3 basic domain contains three non-equivalent furin 
processing sites defined by possessing either a C-1 Arg or Pro.  These data define 
an inverse relationship between processing and potency, providing an important 
new mechanism for post-translational regulation of Sema3 activity.  It was 
previously thought that furin processing simply functioned as a binary activation 
mechanism.  However, our data indicates that the coupled relationship between 
differential furin processing and Nrp engagement allows production of Sema3 
forms with a range of biological activities (Figure 4.6, C).  This provides insight into 
the mechanistic basis for functional differences for Sema3 both in situ and in vivo. 
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CHAPTER 5: STRUCTURAL BASIS FOR NRP2 FUNCTION AS A VEGF-C 
RECEPTOR 
INTRODUCTION 
The VEGF family of cytokines are critical regulators of endothelial cell 
function. There are five VEGF family members: VEGF-A, -B, -C, -D and placental 
growth factor (PlGF). Of these five, VEGF-C and VEGF-D selectively control 
lymphangiogenesis. While they show partially overlapping biological activity and 
physical properties, VEGF-C is essential for viability while VEGF-D is not (Baldwin 
et al., 2005; Karkkainen et al., 2004). Endothelial cells of homozygous VEGF-C 
knockout mice do not sprout to form lymphatic vessels, which results in an 
alymphatic embryo and embryonic lethality (Karkkainen et al., 2004). 
Overexpression of VEGF-C results in selective induction of lymphatic but not 
vascular endothelial cell proliferation and lymphatic vessel enlargement (Jeltsch et 
al., 1997). In addition to its critical physiological role, VEGF-C signaling is also 
important for pathological lymphangiogenesis that is associated with both aberrant 
loss of function in lymphedema (Saaristo et al., 2002) or gain of function in 
tumorigenesis and metastasis (Caunt et al., 2008; Ellis, 2006; Stacker et al., 2002).  
VEGF-C signals via the coordinated activity of two families of endothelial 
cell surface receptors, the VEGFR family of receptor tyrosine kinases (RTK) (rev. 
in (Stuttfeld and Ballmer-Hofer, 2009)) and the Nrp family of co-receptors (rev. in 
(Parker et al., 2012a)). VEGF-C function is specifically mediated through VEGFR-
2/3 (Joukov et al., 1996; Kukk et al., 1996; Lymboussaki et al., 1999) and Nrp2 
(Karkkainen et al., 2001; Xu et al., 2010), with VEGF-C capable of simultaneously 
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engaging both families of receptors (Favier et al., 2006).  VEGFR-2/3 have dual 
functionality in both angiogenesis and lymphangiogenesis (rev. in (Lohela et al., 
2009)).  In contrast, Nrp2 knockout mice display normal angiogenesis but 
abnormal lymphatic vessel development (Yuan et al., 2002), similar to the tissue 
specific function observed in the VEGF-C knockout (Karkkainen et al., 2004). 
Intriguingly, it has also been demonstrated that Nrp2 can function in VEGF-C 
signaling independent of its role as a co-receptor for VEGFR (Caunt et al., 2008). 
Each member of the VEGF family of ligands is produced in multiple forms 
by either alternative splicing (e.g. VEGF-A, -B, and PlGF) or proteolytic processing 
(e.g. VEGF-C and -D) (Holmes and Zachary, 2005). In all cases, an invariant core 
cystine-knot domain, which specifically interacts with VEGFR, is combined with a 
variable C-terminal domain. VEGF-C is synthesized as a pro-protein with N- and 
C-terminal domains flanking the central core cystine-knot domain. Prior to 
secretion, the C-terminal propeptide is cleaved followed by extracellular cleavage 
of the N-terminus (Joukov et al., 1997).  These processing events critically alter 
both the physiological and pathological bioactivity of VEGF-C.  The mature dual 
processed VEGF-C shows dramatically enhanced stimulatory activity in situ 
(Joukov et al., 1997; McColl et al., 2003) and loss of C-terminal processing ablates 
function in vivo (Khatib et al., 2010). However, the physical basis for the enhanced 
activity of the mature form of VEGF-C remains unclear and has been connected 
to different properties including differential receptor binding and interactions with 
heparin/extracellular matrix (ECM) (Harris et al., 2013; Joukov et al., 1997; 
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Karpanen et al., 2006).  The role of VEGF-C proteolytic maturation in regulating 
Nrp2 binding is unknown. 
The structural basis for VEGF-C binding to VEGFR-2/3 has recently been 
elucidated and was shown to involve the invariant cystine-knot domain of VEGF-
C binding to the N-terminal domains of VEGFR-2 and VEGFR-3 (Leppanen et al., 
2010; Leppanen et al., 2013).  However, the structural basis for VEGF-C binding 
to Nrp2 remains to be determined.  Alternative splicing and proteolysis modify the 
C-terminal variable region of VEGF and regulate Nrp binding (Makinen et al., 1999; 
Parker et al., 2012c; Soker et al., 1998).  It has been demonstrated that Nrp1 binds 
the C-terminal basic domain of Sema3 and VEGF family of ligands (He and 
Tessier-Lavigne, 1997; Soker et al., 1996) utilizing a binding pocket for ligands that 
contain a C-terminal arginine (Parker et al., 2010; Parker et al., 2012c; Vander 
Kooi et al., 2007; von Wronski et al., 2006). As demonstrated in Chapters 3 and 4, 
the Sema3 family of ligands undergoes furin-dependent proteolytic maturation 
within their C-terminal domain, a process that liberates an extended basic 
sequence and directly regulates bioactivity and Nrp binding (Adams et al., 1997; 
Parker et al., 2010; Parker et al., 2013). 
Nrp2-dependent VEGF-C signaling is important in a variety of tumors and 
overexpression of these factors is correlated with advanced stage disease and 
poor prognosis (Ellis, 2006; Stacker et al., 2002). Thus, specific Nrp2/VEGF-C 
inhibitors are of clinical interest.  Soluble receptor fragments are common 
endogenous inhibitors (Albuquerque et al., 2009; Ambati et al., 2006; Kendall and 
Thomas, 1993; Rose-John and Heinrich, 1994).  They can also be engineered for 
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use clinically, including VEGF-trap (Aflibercept), a chimeric VEGFR-1/2-Fc fusion, 
which is an inhibitor of VEGF-A (Holash et al., 2002).  A soluble splice form of 
Nrp2, s9Nrp2, has been identified at the transcript level (Rossignol et al., 2000). 
s9Nrp2 is produced by intro inclusion, which contains an in-frame stop codon.  This 
stop codon is located prior to the transmembrane domain, and is thus predicted to 
produce a secreted form of Nrp2. Interestingly, the insertion occurs in the middle 
of the second coagulation factor domain (b2), rather than in an interdomain region. 
The two Nrp2 coagulation factor domains (b1b2) form an integral unit (Appleton et 
al., 2007) and thus the nature of the production and function of s9Nrp2 is unclear. 
Further, domains b1b2 of Nrp2 have been demonstrated to bind VEGF-C 
(Karpanen et al., 2006), bringing into question whether this soluble splice form 
contains the structural requirements necessary to bind and sequester its ligands. 
Here we demonstrate that removal of the VEGF-C C-terminal propeptide 
directly regulates binding to Nrp2. The structure of the mature VEGF-C C-terminus 
in complex with Nrp2 demonstrates that a cryptic Nrp2-binding motif is liberated 
upon C-terminal processing. This offers the first structural insight into the physical 
basis for VEGF-C binding to Nrp2, showing that the proteolytically liberated C-
terminal arginine of VEGF-C directly binds the Nrp2 b1 domain. Mutagenesis of 
both VEGF-C and Nrp2 confirms the critical nature of the VEGF-C C-terminal 
sequence in Nrp2-b1 binding. Understanding the physical interactions underlying 
VEGF-C/Nrp2 binding led us to consider mechanisms for VEGF-C inhibition.  The 
secreted Nrp2 splice form, s9Nrp2, contains an intact Nrp2 b1 domain but a 
subsequent stop codon, and we assessed its function as a pathway specific 
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inhibitor. Strikingly, this soluble receptor forms a disulfide-linked dimer with two 
tightly integrated b1 domains and functions as a potent inhibitor of VEGF-C binding 
to Nrp2. 
RESULTS 
Structural basis for proteolytic-dependent VEGF-C binding to Nrp2  
VEGF-C is synthesized as a pro-protein with N and C-terminal propeptides. 
Removal of the VEGF-C C-terminal propeptide critically regulates its bioactivity.  
C-terminal processing of VEGF-C liberates a polypeptide stretch rich in basic 
amino acids that terminates with a di-arginine sequence (Figure 5.1, A), a 
structural motif conserved across the VEGF and Sema3 family of ligands and 
known to be important for Nrp1 binding. Thus, we hypothesized that processing of 
VEGF-C may directly regulate a physical interaction with Nrp2.  To test this 
hypothesis, we produced peptides corresponding to the unprocessed (215-
RQVHSIIRRSLPA-227) and processed (215-RQVHSIIRR-223) VEGF-C C-
terminus and measured the ability of each peptide to bind Nrp2 domains b1b2 
using a differential scanning fluorimetry (DSF) thermal shift assay (Figure 5.1, B). 
Processed VEGF-C significantly stabilized Nrp2-b1b2 (Tm 48.8°C ± 0.06°C to 
50.3°C ± 0.05°C), while unprocessed VEGF-C showed no effect (Tm  48.4°C ± 
0.04°C). Further, the processed VEGF-C peptide showed dose-dependent 
saturable binding to Nrp2-b1b2 with an apparent dissociation constant (Kd) = 199 
μM ± 71 μM (Figure 5.1, C).  These data demonstrate that C-terminal proteolytic 
maturation directly regulates VEGF-C binding to Nrp2. 
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 To define the physical basis for proteolytic-dependent binding of VEGF-C 
to Nrp2, we determined the crystal structure of the processed VEGF-C C-terminus 
in complex with Nrp2 domains b1b2. The C-terminal five amino acids of mature 
VEGF-C (219-SIIRR-223), which are strictly conserved across species and also 
with VEGF-D, were fused to the C-terminus of human Nrp2 domains b1b2 
(residues 276-595). The fusion protein was expressed in E. coli, purified, and 
crystallized. The structure was solved by molecular replacement and was refined 
to a resolution of 1.9 Å (Figure 5.1, D, Table 1). Clear electron density for the 
VEGF-C-encoded region was observed and manually built.  There were two 
molecules in the asymmetric unit oriented in an anti-parallel fashion. Both 
molecules demonstrated specific binding of the VEGF-C encoded residues via an 
intermolecular interaction with a symmetry-related molecule. 
 Analysis of the structure reveals that VEGF-C (green) engages a binding 
pocket formed by the Nrp2-b1 (blue) coagulation factor loops (Figure 5.1, D). 
Indeed, this interloop cleft uniquely accommodates the C-terminal residue of 
processed VEGF-C (Figure 5.1, E). The free carboxy-terminus of VEGF-C is 
integrated into the binding pocket through interactions with residues from the third 
coagulation factor loop (L3) of Nrp2-b1, which form a wall at one side of the binding 
pocket (“C-wall”).  Specifically, an extensive hydrogen bond network forms 
between the VEGF-C free C-terminal carboxylate and the side chains of the C-wall 
residues S349, T352, and Y356 (Figure 5.1, E). Importantly, the position of the C-
wall would preclude binding of the unprocessed protein, providing a physical 
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mechanism for the observed proteolytic-dependent binding of VEGF-C to Nrp2-
b1b2. 
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Figure 5.1: Crystal structure of the VEGF-C/Nrp2 complex reveals the basis 
for proteolytic-dependent binding.  
(A) Organization of the VEGF-C pro-protein and site of C-terminal processing 
(black arrow). (B) Peptides corresponding to processed (green) and unprocessed 
(black) VEGF-C were assayed for the ability to bind Nrp2-b1b2 as measured by 
differential scanning fluorimetry (DSF) thermal shift assays. Peptides were added 
to Nrp2-b1b2 to a final concentration of 0.5 mM and melting was monitored 
between 20 and 90°C. All samples were measured in triplicate and a 
representative melting curve is shown for each. (C) Processed VEGF-C dose-
dependently enhances the Nrp2-b1b2 Tm. Error bars indicate the standard 
deviation of three measurements. (D) Structure of Nrp2-b1b2 (blue) in complex 
with the C-terminus of VEGF-C (green). (E) Cross-section of the Nrp2 binding 
pocket demonstrates that the free carboxy terminus of VEGF-C is buried against 
the Nrp2 C-wall, which is formed by the third coagulation factor loop. 
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Characterization of the VEGF-C/Nrp2 interaction  
 The clear electron density present at the Nrp2-b1 interloop cleft permitted 
modeling of both the VEGF-C polypeptide and interfacing solvent that bridge the 
two molecules (Figure 5.2, A).  Analysis of the VEGF-C/Nrp2 interface reveals 
direct interactions between VEGF-C and residues within the L1, L5, and L3 loops 
of Nrp2-b1 (Figure 5.2, B). In addition to the hydrogen bond network formed 
between the VEGF-C free carboxy-terminus and the Nrp2 L3 loop, the side chain 
of the VEGF-C C-terminal arginine, R223, forms extensive interactions with the 
Nrp2 binding pocket.  The gaunidinium of VEGF-C R223 forms a salt-bridge with 
the Nrp2-b1 L5 loop residue D323. Additionally, the aliphatic portion of the R223 
side chain displays extensive van der Waals interactions with two tyrosine residues 
of Nrp2-b1 that demarcate the sides of the binding pocket, Y299 (L1 loop) and 
Y356 (L3 loop). In addition to interactions mediated by VEGF-C R223, there is a 
hydrogen bond between the backbone carbonyl of I221 and the aromatic hydroxyl 
of Nrp2 Y299.   
 While protein-protein binding is primarily mediated by direct interactions 
between polypeptide chains, interfacing solvent also plays a critical role in 
stabilizing protein-protein complexes (Janin, 1999; Karplus and Faerman, 1994). 
Three water molecules, two of which bridge the interaction between VEGF-C and 
Nrp2, are observed in the binding site. One solvent molecule facilitates a water-
mediated hydrogen bond between the side chain hydroxyl of Nrp2 T319, located 
at the base of the binding pocket, and the side chain gaunidinium of VEGF-C R223 
(Figure 5.2, B). Likewise, a second solvent molecule bridges the side chain 
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carboxylate of Nrp2 E351 and the free carboxylate of VEGF-C. These solvent-
mediated interactions appear to further stabilize the position of the VEGF-C C-
terminus within the Nrp2-b1 binding pocket. 
 To confirm the critical role of the VEGF-C C-terminus we mutated the C-
terminal arginine of VEGF-C to glutamate (R223E) and compared the ability of 
alkaline phosphatase (AP)-tagged VEGF-C and VEGF-C R223E to bind Nrp2-
b1b2 affinity plates (Figure 5.2, C).  Robust binding was observed between AP-
VEGF-C and Nrp2-b1b2 but R223E binding was reduced by >95%. These data 
demonstrate that the C-terminal arginine of mature VEGF-C is necessary for high-
affinity Nrp2-b1b2 binding, and confirm the importance of C-terminal propeptide 
processing within VEGF-C to produce a C-terminal arginine that allows avid 
engagement of Nrp2. 
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Figure 5.2: Mechanism of VEGF-C binding to Nrp2. 
(A) Zoom of the intermolecular interface between Nrp2 (blue) and VEGF-C (green) 
with the 2Fo-Fc electron density map for VEGF-C contoured at 1.0σ. Interfacing 
water is shown as grey spheres. (B) Ligplot+ generated representation of the 
interaction between VEGF-C (green) and Nrp2 (blue). Bond distances (Å) are 
labeled in black and water is shown as grey spheres. (C) Nrp2 binding was 
compared between VEGF-C and VEGF-C R223E. Binding was analyzed in 
triplicate for each construct and the data is plotted as the mean ± standard 
deviation. 
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Occluding the Nrp2 interloop cleft abolishes binding  
 The structure of VEGF-C in complex with Nrp2 reveals a critical role for the 
Nrp2-b1 interloop cleft, which forms the VEGF-C binding pocket. To confirm that 
the Nrp2 binding pocket is responsible for VEGF-C binding, we carried out site-
directed mutagenesis against Nrp2-b1b2 to generate a construct with an occluded 
binding pocket. Specifically, the residue at the base of the Nrp2-b1 interloop cleft, 
T319, was mutated to arginine (Nrp2-T319R).  We determined the crystal structure 
of Nrp2-T319R to a resolution of 2.4 Å (Figure 5.3, A, Table 1). The R319 side-
chain showed clear electron density extending into the interloop cleft between the 
two binding pocket tyrosines, Y299 and Y356 (Figure 5.3, B). Superposing the 
VEGF-C/Nrp2 complex onto Nrp2-T319R demonstrates that the binding site 
occupied by VEGF-C is occluded in the Nrp2 mutant (Figure 5.3, C). The Nrp2-
T319R mutant was then used to analyze the contribution of the interloop cleft to 
VEGF-C binding. We compared the binding of VEGF-C to Nrp2-b1b2 and Nrp2-
T319R (Figure 5.3, D). While robust binding was observed between AP-VEGF-C 
and Nrp2-b1b2, binding to Nrp2-T319R was completely abolished. These data 
confirm that the interloop cleft, formed by the Nrp2-b1 coagulation factor loops, 
forms a structure that uniquely accommodates the C-terminus of VEGF-C to 
mediate binding of the C-terminally processed ligand. 
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Figure 5.3: Crystal structure and VEGF-C binding properties of Nrp2-T319R.  
(A) Structure of Nrp2-T319R with the stick representation for T319R shown in red. 
(B) Zoom of the Nrp2-T319R binding pocket. The blue mesh illustrates the 2Fo-Fc 
electron density map for R319 contoured at 1.0σ. (C) Superimposition of VEGF-C 
(green) onto the structure of Nrp2-T319R demonstrates that the binding pocket 
normally occupied by VEGF-C is blocked in the mutant. (D) VEGF-C binding was 
compared between Nrp2-b1b2 and Nrp2-T319R. Binding was analyzed in triplicate 
for each construct and the data is plotted as the mean ± standard deviation. 
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A dimeric soluble Nrp2 splice form 
 Based on the specific binding of VEGF-C to the Nrp2 b1 domain, we 
hypothesized that the previously identified splice form of Nrp2, s9Nrp2, could 
function as a selective inhibitor of VEGF-C.  s9Nrp2 is an alternative Nrp2 splice 
form that arises from intron inclusion in the b2 domain.  An in-frame stop-codon 
encoded within the intron is predicted to result in termination of translation prior to 
the transmembrane domain, and thus production of a secreted Nrp2 receptor.  
Given that the b1 domain of Nrp2 is solely responsible for VEGF-C binding, we 
hypothesized that s9Nrp2 may be able to effectively sequester VEGF-C, thereby 
functioning as an inhibitor.  However, it is unknown whether the s9Nrp2 transcript 
produces a functional protein, since s9Nrp2 retains residues coding only a portion 
of the b2 domain (114 of 159 residues). Indeed, s9Nrp2 lacks the coding region for 
three of the eight core β-strands that normally integrate to form the distorted jelly-
roll fold that typifies the b1 and b2 domains of Nrp. Additionally, it was unknown 
whether s9Nrp2 could accommodate the loss of the b2 C-terminal capping cysteine 
and the introduction of an alternative cysteine encoded by the intronic sequence. 
To investigate the physical and functional activity of s9Nrp2, we expressed and 
purified the coagulation factor domain residues of s9Nrp2 (Figure 5.4, A, s9Nrp2B: 
residues 275-547, plus the unique intron encoded sequence VGCSWRPL). 
Analysis of s9Nrp2B by reducing SDS-PAGE revealed that purified s9Nrp2B, while 
running with a larger apparent MW than Nrp2-b1 alone, was smaller than expected 
from its primary sequence (Figure 5.4, B, observed MW = 22 kDa, expected MW 
= 34 kDa).  Mass spectrometry confirmed that s9Nrp2B is an essentially 
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homogeneous single species with MW = 22,775 Da ± 20 Da. These data, together 
with the observed intact N-terminal His-tag, indicate that s9Nrp2B is cleaved C-
terminal to E457 (predicted MW = 22,792 Da). Thus, the proteolyzed s9Nrp2B 
contains only a single cysteine residue from the b2 domain (C434), which normally 
forms an intradomain disulfide. Surprisingly, under non-reducing conditions, 
s9Nrp2B ran with an apparent MW = 38 kDa, indicating the formation of a disulfide-
linked intermolecular dimer via the free b2 domain cysteine (Figure 5.4, B).  The 
difference in oligomeric state was evident from size exclusion chromatography 
(SEC) (Figure 5.4, C). Nrp2-b1 eluted off SEC with an apparent MW = 16 kDa 
(grey line), while s9Nrp2B had an apparent MW = 38 kDa (black line), consistent 
with the SDS-PAGE analysis. 
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Figure 5.4: s9Nrp2B unexpectedly forms a disulfide-linked dimer.  
(A) Domain organization of Nrp2 and the protein fragment utilized for our studies, 
s9Nrp2B. (B) Non-reducing and reducing SDS-PAGE analysis of Nrp2-b1 and 
s9Nrp2B. (C) The oligomeric state of s9Nrp2B (black line) was analyzed by size-
exclusion chromatography. Nrp2-b1 was run as a reference (grey line). 
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s9Nrp2B is a uniquely potent inhibitor of VEGF-C/Nrp2 binding  
 To understand the structural arrangement of the s9Nrp2B dimer, we 
determined the crystal structure of s9Nrp2B to a resolution of 2.4 Å (Figure 5.5, A, 
Table 5.1).  Continuous electron density was observed from F275 through S453, 
consistent with the mass spectrometry defined C-terminus. A single dimer was 
present in the asymmetric unit, with the base of each b1 domain apposed to the 
other, thus forming an extended anti-parallel dimer. The orientation of the dimer is 
stabilized by both the intermolecular disulfide and, unexpectedly, a unique dimeric 
helical bundle formed by residues from the b1-b2 linker and b2 domain (Figure 5.5, 
B).  The residues that form this unique helix (residues 428-453) display dramatic 
structural reorganization relative to that observed in the intact b2-domain where 
they form an extended sheet and loop motif (Figure 5.5, C).  The C-terminal helix 
runs approximately 20° off parallel from the base of the b1 domain, an angle that 
is maintained by a cluster of hydrophobic residues at the hinge region between the 
helix and domain b1. The helix both caps the b1 domain and mediates the 
intermolecular interaction interface with the other monomer of the s9Nrp2B dimer. 
The intermolecular interface is composed of both helix-helix interactions, which are 
mostly hydrophobic in nature (Figure 5B), and helix-b1 interactions, which are 
mostly hydrophilic in nature. 
 The two binding pockets within the s9Nrp2B dimer are positioned 71 Å apart, 
suggesting that it could simultaneously engage both subunits of the VEGF-C 
dimer, which is 68 Å wide (Leppanen et al., 2010).  Thus, we hypothesized that co-
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engagement of both VEGF-C monomers by s9Nrp2B would allow the dimer to 
function as a uniquely potent inhibitor of VEGF-C/Nrp2 binding. To test this 
hypothesis, we compared the inhibitory potency of ATWLPPR, an optimized 
peptide inhibitor of Nrp that functions by competitive binding (Parker and Vander 
Kooi, 2014; Starzec et al., 2007), with Nrp2-b1 and s9Nrp2B, both of which function 
as soluble competitors through sequestration of VEGF-C (Figure 5.5, D). 
ATWLPPR showed dose dependent inhibition of VEGF-C binding to Nrp2 with an 
IC50 = 10 M (black line), consistent with its modest reported potency.  Next, we 
examined the ability of Nrp2-b1 to inhibit binding (grey line). Nrp2-b1 sequestered 
VEGF-C with improved potency compared to the peptide inhibitor, with an IC50 = 
1.5 M. As expected for a monomeric competitive inhibitor, the Hill slope was 
approximately -1 (ATWLPPR = -1.08 and Nrp2-b1 = -0.97). These data are 
consistent with independent engagement of each VEGF-C monomer by a single 
Nrp2-b1. Next, we measured the inhibitory potency of s9Nrp2B (orange line). 
Strikingly, s9Nrp2B potently sequestered VEGF-C with an IC50 = 250 nM, a 
significant improvement in potency from both the peptide inhibitor and Nrp2-b1. 
Additionally, the Hill slope for s9Nrp2B was -1.5. Thus, the enhanced potency of 
s9Nrp2B is due to its ability to synergistically sequester the VEGF-C dimer through 
simultaneous and cooperative engagement of the two VEGF-C monomers. These 
data demonstrate that s9Nrp2B is a potent inhibitor of VEGF-C and represents an 
exciting avenue for production of a lymphangiogenic inhibitor 
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Figure 5.5: Crystal structure and inhibitory properties of s9Nrp2B.  
(A) Crystal structure of the s9Nrp2B dimer (Chain A: light orange; Chain B: dark 
orange). The Nrp2-b1 binding pockets are labeled with black arrows. (B) Zoom of 
the dimeric helical bundle with the 2Fo-Fc electron density map contoured at 1σ. 
(C) The residues of the Nrp2 b1-b2 linker and b2 domain show a dramatic 
structural reorganization from an extended loop in the b1b2 sequence (blue) to an 
extended helix in the s9Nrp2B dimer (orange). (D) The inhibitory potency of 
ATWLPPR, Nrp2-b1, and s9Nrp2B against blocking VEGF-C/Nrp2 binding was 
measured. ATWLPPR inhibited binding with an IC50 50] = -4.98 ± 
0.03), Nrp2-b1 inhibited binding with an IC50 50] = -5.82 ± 0.09), 
and s9Nrp2B inhibited binding with an IC50 = 250 nM (log[IC50] = -6.60 ± 0.08). 
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Inhibition was measured in triplicate and the data is plotted as the mean ± standard 
deviation.  
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DISCUSSION 
Structural characterization of the mechanism for VEGF-C binding to Nrp2 
represents an important step for understanding the physiological and pathological 
activity of VEGF-C.  These data also inform the rationale design of specific VEGF-
C/D antagonists, including s9Nrp2B, which potently inhibits VEGF-C/Nrp2 binding 
and represents a potential therapeutic avenue. Collectively, these results have 
important implications for interpreting both the aberrant loss and gain of function 
in the VEGF-C/Nrp2 signaling axis that critically underlies a number of disease 
states. 
With complementary biochemical and structural approaches we show that 
VEGF-C C-terminal proteolysis is required for Nrp2 binding. The requirement for 
proteolytic processing is determined by the position of the Nrp2 C-wall, formed by 
the L3 coagulation factor loop residues, which specifically engages the VEGF-C 
free carboxy-terminus, precluding binding of unprocessed protein.  These results 
provide critical insight for interpreting the altered in vitro and in vivo functionality of 
alternative VEGF-C forms. While both N- and C-terminal processing regulate 
VEGF-C activity (Joukov et al., 1997; McColl et al., 2003), processing at these 
sites is not functionally equivalent. Indeed, loss of C-terminal processing is 
uniquely detrimental, fully ablating VEGF-C function in vivo (Khatib et al., 2010), 
which we demonstrate blocks Nrp2 binding.  
Determining the structural basis for VEGF-C signaling via Nrp2 informs 
ongoing studies to describe the effect of signaling deficiency on human disease.  
Deficient VEGF-C signaling via Nrp2 has significant implications for both primary 
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and secondary lymphedema.  Mutations in both VEGFR-3 (Karkkainen et al., 
2000) and VEGF-C (Gordon et al., 2013) have been demonstrated to underlie 
hereditary lymphedema and Nrp2 has been identified as an additional candidate 
gene (Ferrell et al., 2008; Karkkainen et al., 2001) Additionally, both VEGF-C and 
Nrp2 have recently been identified as candidate genes for the development of 
secondary lymphedema following surgery in breast cancer (Miaskowski et al., 
2013). The structural insights gleaned from the VEGF-C/Nrp2 complex also 
provide an important molecular basis for interpreting emerging exome sequencing 
data that has identified Nrp2 variants in close proximity to the ligand binding 
interface. Intriguingly, a stringent examination of exome sequencing data has 
reported both common and rare Nrp2 variants in human populations (Tennessen 
et al., 2012).  Several of these variants are located in the coagulation factor loops 
of Nrp2-b1, the region to which VEGF-C binds. Specifically, there are two reported 
variants in the L5 loop (N321I and L322M) that are located proximal to the critical 
salt-bridge formed by D323, and two in the L3 loop (Q353H and N354K). The 
structural data presented here provides a rationale for examining specific 
coagulation loop variants for loss of function on both a physical and functional 
level. 
These results provide critical insight into the physical basis for VEGF-C 
binding to its receptor, Nrp2. We demonstrate that the C-terminal residues of 
VEGF-C, particularly the VEGF-C C-terminal arginine (R223), engage a binding 
pocket within the Nrp2-b1 domain. Interestingly, previous studies have implicated 
a non-C-terminal domain within VEGF-A that is responsible for Nrp1 binding. This 
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motivates studies aimed at understanding the differences between VEGF-A and 
VEGF-C engagement of their cognate receptors, Nrp1 and Nrp2, respectively.  
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Table 5.1: Data collection and refinement statistics 
Construct: Nrp2-VEGF-C Nrp2-T319R s9Nrp2B 
Data Collection 
Beamline APS 22-ID APS 22-BM APS 22-ID 
Wavelength 1.0000 1.0000 1.0000 
Space group P21 P212121 P21212 
Cell dimensions (Å) 41.05, 120.81, 
69.84 
34.90, 70.76, 
122.97 
69.36, 91.39, 
67.33 
Cell dimensions (°) 90.0, 103.29, 
90.0 
90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Unique reflections 44,081 12,223 16,303 
Completeness (%) 90.6(82.0) 96.4(83.2) 94.1(79.8) 
Resolution (Å) 1.95(2.02-1.95) 2.40(2.49-2.40) 2.40(2.49-2.40) 
Rmerge (%) 9.9(46.6) 8.0(29.2) 9.9(32.7) 
Redundancy 5.1(4.2) 6.8(5.9) 4.4(4.1) 
I/σ(I) 13.1(3.0) 29.4(5.1) 12.3(3.2) 
Refinement 
Resolution limits (Å) 20.00(1.95) 20.00(2.40) 20.00(2.40) 
No. reflections/no. to compute Rfree 41,511/2140 11,490/586 15,439/821 
R(Rfree) 21.0(24.1) 20.1(25.5) 21.0(26.4) 
No. protein residues 632 313 361 
No. solvent/ion molecules 333 123 107 
RMSD Bond, Å 0.006 0.008 0.006 
RMSD Angle, ° 1.11 1.19 1.04 
Protein geometry 
Ramachandran outlier/favored (%) 0/96.7 0/96.1 0/96.7 
Residues with bad bonds/angles 0/0 0/0 0/0 
Rotamer outliers 0 0 0 
Table 5.1: Data collection and refinement statistics for Chapter 5 
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CHAPTER 6: STRUCTURAL BASIS FOR SELECTIVE VEGF-A BINDING TO 
NRP1 
Introduction 
 Nrp1 is essential for VEGF dependent angiogenesis (rev. in (Pellet-Many et 
al., 2008)).  The importance of Nrp1 function in vivo is illustrated by Nrp1 null mice, 
which show embryonic lethality due to cardiovascular defects (Kawasaki et al., 
1999).  In angiogenesis, Nrp1 functions with the VEGFR family of receptor tyrosine 
kinases.  Nrp1 is necessary for high affinity ligand binding to the cell surface and 
specifically promotes and stabilizes the active angiogenic signaling complex 
involving VEGF-A, VEGFR-2, and Nrp1 (rev. in (Grunewald et al., 2010)). 
 The VEGF-A gene is encoded by nine exons.  A cystine knot domain, 
encoded by exons 1-5, is retained in all VEGF-A isoforms.  This domain is essential 
for signaling, mediating homo-dimerization, and direct interaction with VEGFR 
(Keyt et al., 1996).  Alternative splicing of the remaining introns produces VEGF-A 
molecules with varying activity, extracellular matrix binding and diffusibility (Houck 
et al., 1992).  It has long been recognized that the most potent stimulator of 
angiogenesis is VEGF-A164/5, named for the total number of amino acid residues 
in mouse and human proteins, respectively.  VEGF-A164 possesses a heparin 
binding domain (HBD) encoded by exons seven and eight (Fairbrother et al., 1998; 
Leung et al., 1989).  It has been demonstrated that Nrp1 binds to the VEGF-A HBD 
(Soker et al., 1996) via its b1 coagulation factor domain (Gu et al., 2002; Mamluk 
et al., 2002; Soker et al., 1998).  However, the nature and extent of the interaction 
is not clear and has been the source of considerable study. 
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 It was initially thought that exon seven encoded residues represented the 
Nrp-binding region of VEGF-A, thus explaining the significant differences in the 
biological potency of different VEGF-A isoforms (Soker et al., 1998).  In contrast to 
VEGF-A164, VEGF-A120 differs by exclusion of exon seven.  The clear biological 
role of exon seven encoded residues in determining the ability of the cytokine to 
activate endothelial cells has been demonstrated in situ and in vivo (Keyt et al., 
1996; Soker et al., 1997).  However, subsequent studies demonstrated that the 
conserved exon eight encoded C-terminus of VEGF-A controls Nrp binding.  All 
pro-angiogenic VEGF-A isoforms retain exon eight while an inhibitory VEGF splice 
form, VEGF-A165b, replaces exon eight with exon nine encoded residues (Bates et 
al., 2002).  Nrp binding was isolated to the C-terminal portion of the VEGF-A HBD 
and a critical role was established for exon eight encoded residues (Jia et al., 
2006).  Further, Tuftsin, an immuno-stimulatory peptide mimic of VEGF-A exon 
eight, was found to inhibit VEGF-A binding to Nrp1, while not affecting VEGF-A 
binding to VEGFR-2 (von Wronski et al., 2006).  It was further shown that Nrp 
possesses a specific C-terminal arginine binding pocket located in the Nrp1-b1 
domain (Vander Kooi et al., 2007).  All known Nrp binding proteins and peptides 
have been shown to posses a C-terminal arginine (Parker et al., 2010; Starzec et 
al., 2007; Teesalu et al., 2009; Vander Kooi et al., 2007).  Indeed, it was 
convincingly demonstrated that VEGF-A165 and VEGF-A121 both bind Nrp1, 
although with different kinetics and affinity (Pan et al., 2007b).  This has left the 
physical role of exon seven in receptor binding now unclear. 
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 There are two Nrp genes in higher vertebrates, Nrp1 and Nrp2, which share 
44% identity in their primary sequence and have the same overall domain 
organization (Kolodkin et al., 1997).  Although Nrp1 and Nrp2 are structurally 
related, they facilitate activation of functionally distinct pathways utilizing different 
members of the VEGF family. Nrp1 primarily mediates VEGF-A dependent 
angiogenesis (Soker et al., 1998) whereas Nrp2 primarily mediates VEGF-C 
dependent lymphangiogenesis (Xu et al., 2010).  Nrps involvement in multiple 
physiological processes poses the unique challenge of isolating activation events 
to prevent inadvertent crosstalk.  Differential ligand binding and temporal and 
tissue specific expression are important regulatory mechanisms controlling Nrp 
function (rev. in (Staton et al., 2007)).  Differential ligand binding has been shown 
to be critical for the specific binding of the VEGF family members to different 
VEGFRs.  For example, VEGF-A binds to VEGFR-1 and VEGFR-2, but with 
approximately fifty-fold higher affinity for VEGFR-1 (Waltenberger et al., 1994).  
Although VEGF binding to VEGFR has been characterized, the nature and basis 
for specific ligand binding to Nrp has not been determined. 
 In order to elucidate the molecular basis for the potent and specific binding 
of VEGF-A164 to Nrp, we have determined the structure of the VEGF-A HBD bound 
to Nrp1.  This structure reveals an intermolecular interface with contributions from 
residues encoded by both exons seven and eight. We characterize these 
interactions and show that the exon eight encoded region determines high-affinity 
interaction with Nrp1.  The exon seven encoded region is found to uniquely 
physically engage Nrp1 and contribute to binding. Strikingly, the exon seven 
 102 
mediated interaction is shown to determine the selective binding of VEGF-A164 to 
Nrp1.  These results define the unique physical mechanism underlying VEGF-A 
binding to Nrp. 
Results  
Physical basis for VEGF-A and Nrp1 binding 
 To understand the basis for Nrp binding of VEGF-A, we determined the 
crystal structure of the VEGF-A HBD in complex with the core ligand binding 
domain of Nrp1, domain b1. There were two molecules in the asymmetric unit, with 
intermolecular interactions between the VEGF-A HBD and Nrp-b1 (Figure 6.1, A, 
Table 6.1).  The VEGF-A HBD of Chain A fully engages the Nrp1-b1 moiety of 
Chain B and reveals an extended intermolecular interaction interface between 
VEGF-A and Nrp1 (gold) (Figure 6.1, B).  The intermolecular interface is formed 
by both exon seven (blue) and eight (green) encoded residues of the VEGF-A HBD 
(Figure 6.1, B).  Analysis of the HBD/Nrp1-b1 complex reveals that the interface is 
predominantly hydrophilic in nature and is stabilized by a network of hydrogen 
bonds and salt bridges.  The HBD retains the overall structural architecture 
previously determined (Fairbrother et al., 1998), with an R.M.S.D. of 2.0Å 
(overlaying residues 115-164). The orientation of the C-terminal peptide-like exon 
eight encoded residues is significantly different from that observed in solution.  This 
unique orientation is due to the presence of an intramolecular salt-bridge formed 
between D142 and R163 as well as its direct association with Nrp1 (Figure 6.1, C 
& D).  The Nrp1 b1 domain shows no significant differences from previously 
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determined structures with a R.M.S.D. of 0.8Å (PDB=2QQI, overlaying residues 
274-429).  
  
 104 
 
 
 
Figure 6.1: The crystal structure of the VEGF-A HBD in complex with Nrp1. 
 (A) Chain A (green) and Chain B (blue) crystallized in an anti-parallel fashion with 
the Chain A VEGF-A HBD fully engaging the Nrp1-b1 domain of Chain B, and that 
of Chain B engaged by the symmetry related Nrp1-b1 domain of Chain A.  The 
intermolecular complex enclosed in the dashed box is shown in (B) A space-filling 
model revealing the specific interface with VEGF-A164 exon seven and eight (Chain 
A) encoded residues with Nrp1 (Chain B).  (C) A stereo view of the 2FO-FC electron 
density map contoured at 1.0 sigma of Nrp1 (gold) and exon seven (blue) and eight 
(green) of VEGF-A164. An intramolecular salt bridge between D142 and R163 of 
VEGF-A164 and intermolecular salt-bridge between D320 of Nrp1 and R164 of 
VEGF-A164 are observable. (D) A stereo view of the Fo-Fc omit electron density 
map for the HBD residues contoured at 3.0 sigma 
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Isoform specific binding of VEGF-A to Nrp1  
 Differences in potency, functionality, and receptor binding have been 
reported for VEGF-A164 and VEGF-A120, which differ only in the inclusion of exon 
seven in VEGF-A164.  To delineate the different roles of these exons in Nrp binding, 
the dose dependent binding of AP-VEGF-A164 and AP-VEGF-A120 to Nrp1 was 
analyzed (Figure 6.2).  VEGF-A164 (black line) bound Nrp1 with high affinity, 
Kd=3.0nM±0.2nM.  As expected for high density coupling of Nrp1, the observed 
binding is consistent with the reported tight cell surface binding (Soker et al., 1998).  
VEGF-A120 (gray dashed line) also bound Nrp1, but with lower affinity 
(Kd=22nM±1nM).  These data indicate that both exon eight containing isoforms of 
VEGF-A are able to bind to Nrp1, but differ in their affinity. 
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Figure 6.2: VEGF-A164 binds to Nrp1 with high-affinity.  
VEGF-A164 (black line) binds Nrp1 with a Kd=3.0nM±0.2nM. VEGF-A120 (gray 
dashed line) binds Nrp1 with a Kd=22nM±1nM.  
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Exon eight encoded residues are essential for high-affinity VEGF-A binding 
to Nrp1  
 Close examination of the residues of exon eight that interact with Nrp1 
reveals that VEGF-A164 utilizes a C-terminal arginine (R164) to bind Nrp1 (Figure 
6.3, A).  Analysis of the intermolecular interface in this region indicates that R164 
contributes a majority of the interaction with Nrp1.  While the electron density 
associated with the side-chain indicates some disorder (Figure 6.1, C & D), the 
binding mode is seen in both molecules in the asymmetric unit, and is very similar 
to the previously determined structure with the inhibitory peptide Tuftsin (TKPR), a 
peptide mimic of VEGF-A exon eight (Figure 6.3, B).  R164 is fully engaged by b1, 
burying 247 Å2 in the binding pocket.  A salt-bridge is formed with D320 and the 
free carboxy-terminus forms hydrogen bonds with S346, T349, and Y353 of the b1 
domain (Figure 6.3, A).  
 To characterize the contribution of the exon eight encoded C-terminal 
arginine to binding, we analyzed site-directed mutants of both VEGF-A and Nrp1.  
To determine the role of the salt-bridge, the C-terminal arginine was first mutated 
to alanine (Figure 6.3, C).  Retention of R164A by Nrp1 (black bar) was reduced 
by 97% relative to WT VEGF-A164.  To determine the role of the carboxy-terminal 
hydrogen bond network, a VEGF-A164 construct with a C-terminal di-alanine 
addition was generated.  Retention of R164R+AA by Nrp1 (gray bar) was reduced 
by 87% relative to WT VEGF-A164.  The observed contributions from both side-
chain and carboxy-terminus emphasize the unique requirement for a carboxy-
terminal arginine in high affinity Nrp ligands.  Lastly, a charge reversal was 
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produced. R164E (red bar) showed no significant binding to Nrp1.  These data 
demonstrate the essential role of a carboxy-terminal arginine in VEGF. 
 To complement these results we examined the amount of VEGF-A164 
binding retained when the Nrp1 binding pocket was occluded.  T316, which sits at 
the base of the Nrp1 binding pocket adjacent to D320 (Figure 6.3, D), was mutated 
to arginine to generate a binding-deficient Nrp1 mutant.  The binding of AP-Nrp1 
or AP-T316R to VEGF-A164 was determined (Figure 6.3, E).  Strikingly, occlusion 
of the Nrp1-b1 binding pocket in AP-T316R completely abolished binding with 
VEGF-A164.  These data demonstrate the essential role of the Nrp1-b1 C-terminal 
arginine binding pocket in mediating high-affinity VEGF-A binding.  
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Figure 6.3: The exon eight encoded C-terminal arginine of VEGF-A 
mediates high-affinity Nrp1 binding.  
(A) R164 forms specific contacts with the b1 binding pocket of Nrp1. The 
guanidinium moiety forms a salt-bridge with D320 carboxylate oxygen’s (dashed 
red lines, 3.08Å and 3.32Å). The carboxy-terminus forms hydrogen bonds with 
three Nrp1-b1 residues (dashed gray lines, 3.08Å, 2.95Å, and 3.13Å to S346, 
T349, and Y353, respectively). (B) Tuftsin binds to the Nrp1-b1 domain 
(PDB=2ORZ) utilizing the same C-terminal arginine binding mode. (C) 
Mutagenesis demonstrates a specific role for the side chain (R164A, black bar) 
and carboxy-terminus (R164R+AA, gray bar) in Nrp1 binding.  Charge reversal 
(R164E, red bar) completely abolishes binding to Nrp1. Statistical comparison of 
mean wild-type and mutant binding demonstrates significant differences, 
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p<0.0002, between all constructs. AP tagged wild-type and mutant VEGF was 
used at an activity of 25 μmole p-NPP hydrolyzed/min/μL. (D) A surface 
representation of VEGF-A bound to Nrp1 reveals the critical location of T316 (red) 
and illustrates the mechanism by which mutation to arginine would occlude 
binding. (E) Occlusion of the Nrp1 binding pocket in the Thr-Arg Nrp1 mutant 
(T316R, red bar) completely abolishes binding to VEGF-A164. AP-tagged wild-type 
and mutant Nrp1 was used at an activity of 1 μmole p-NPP hydrolyzed/min/μL.  
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Exon seven residues directly physically engage the L1 loop of Nrp1 
 The enhanced affinity of VEGF-A164 for Nrp1 versus that of VEGF-A120 
suggests a role for the exon seven encoded residues in the interaction with Nrp1.  
The reported structure reveals that specific exon seven encoded residues also 
directly engage Nrp1.  The interface with exon seven encoded residues is more 
extended and involves K146, E151, and E154.  The residue with the largest 
interface contribution is E154, with 67 Å2 buried surface area at the interface.  The 
side chain of E154 forms a hydrogen bond with both the backbone amide and side-
chain hydroxyl of T299 in the Nrp1 L1 loop (Figure 6.4, A).  The role of E154 in Nrp 
binding was examined (Figure 6.4, B).  An E154A (purple bar) mutant showed 
reduced Nrp1 binding, but the reduction was not as pronounced as that observed 
for R164 mutants.  
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Figure 6.4: E154 of VEGF-A164 exon seven contributes to Nrp1 binding.  
(A) E154 interacts with the side chain hydroxyl (bond distance=2.73Å) and 
backbone amide (bond distance=3.16Å) of T299 of the Nrp1 L1 loop. (B) Mutation 
of E154 to alanine (E154A, purple bar) reduces binding to Nrp1 (p<0.0004). AP 
tagged wild-type and mutant VEGF was used at an activity of 25 μmole p-NPP 
hydrolyzed/min/μL. 
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Selective VEGF-A binding to Nrp1  
 Nrp1 and Nrp2 b1 domains are structurally highly homologous (Figure 6.5, 
A).  However, there are regions that are divergent.  The L1 loops of Nrp1 and Nrp2 
have distinct amino acid composition: the Nrp1 L1 loop T299 is replaced by D301 
in the Nrp2 L1 loop.  This replacement would be expected to result in electrostatic 
repulsion of E154 of VEGF-A164.  We generated a Nrp1 L1 loop chimeric mutant, 
replacing the L1 loop of Nrp1 (299-TN-300) with the Nrp2 loop (301-DGR-303), 
and assessed its ability to bind VEGF-A164 (Figure 6.5, B).  This mutant shows a 
75% reduction in its ability to bind VEGF-A164 (gold/cyan bar) relative to WT Nrp1 
(gold bar).  These data directly demonstrate that the VEGF-A164 E154 interaction 
with the L1 loop of Nrp1 contributes to binding.  
 As observed, substitution of the L1 loop of Nrp2 into Nrp1 dramatically 
reduces Nrp1 binding to VEGF-A164.  This led us to consider whether the physical 
interaction we describe may be directly reflected in decreased affinity of VEGF-
A164 for Nrp2.  To test this, we assayed the binding of VEGF-A164 to Nrp2.  In fact, 
VEGF-A164 shows dramatically weaker binding to Nrp2, with approximately fifty-
fold lower affinity (Figure 6.5, C, black line, Kd=150nM±4nM) relative to Nrp1 
(Figure 6.2, black line, Kd=3nM).  Our data suggests that the observed binding 
selectivity may be due to the exon seven encoded residues.  To test this, we 
compared the binding of VEGF-A120 to the two Nrp receptors.  Indeed, binding of 
VEGF-A120 to Nrp2 is unchanged (Figure 6.5, C, gray dashed line, Kd=23nM±1nM) 
from that of Nrp1 (Figure 6.2, gray dashed line, Kd=22nM). 
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 To confirm that the observed binding selectivity involves electrostatic 
repulsion between E154 and Nrp2, we tested the binding of E154A to Nrp2 (Figure 
6.5, D). Indeed, E154A (purple bar) shows three-fold higher retention by Nrp2 
relative to WT VEGF-A164 (blue). 
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Figure 6.5: Exon seven encoded residues of VEGF-A164 are responsible for 
Nrp1 binding selectivity.  
(A) Superimposition of Nrp1 (PDB=1KEX) and Nrp2 b1 domains (PDB=2QQJ, 
residues 276-427) reveals a similar overall architecture, R.M.S.D.=0.7Å, but 
unique amino acid composition of the L1 loop, with Nrp1-T299 and Nrp2-D301 
highlighted in gold and cyan, respectively. (B) Chimeric Nrp1, containing the L1 
loop of Nrp2 (gold/cyan), loses over 75% binding to VEGF-A164 relative to WT Nrp1 
(gold) (p<0.000004). AP-tagged wild-type and mutant Nrp1 was used at an activity 
of 1 μmole p-NPP hydrolyzed/min/μL. (C) VEGF-A120, which lacks exon seven, has 
essentially the same affinity for Nrp2 (gray dashed line, Kd=23nM±1nM) as it does 
for Nrp1. VEGF-A164 retains exon seven and has dramatically reduced affinity for 
Nrp2 (black line, Kd=150nM±4nM) compared to Nrp1. (D) Nrp2 shows three-fold 
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higher retention of E154A (purple bar) relative to WT VEGF-A164 (blue bar) 
(p<0.0003). AP tagged wild-type and mutant VEGF was used at an activity of 25 
μmole p-NPP hydrolyzed/min/μL. 
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Discussion 
 Together, these data demonstrate a mechanism for selective VEGF binding 
to Nrp.  We report the first detailed picture of the structural basis for the binding of 
Nrp1 and VEGF-A.  The interface is shown to involve regions encoded by both 
exons seven and eight and is found to determine splice-form specific receptor 
binding and selectivity (Figure 6).  Together with mutagenesis of key interfacial 
residues, our data define the specific contribution of different regions of VEGF-A.  
The exon eight encoded C-terminus of VEGF-A is confirmed to be necessary for 
high-affinity Nrp binding.  The C-terminal arginine of VEGF-A is shown to engage 
the Nrp1-b1 domain binding pocket utilized by all known ligands (Parker et al., 
2010; Starzec et al., 2007; Teesalu et al., 2009; Vander Kooi et al., 2007).  A 
number of mutations to residues in the C-terminal arginine binding pocket have 
been reported (Herzog et al., 2011).  These mutations modulate binding to Nrp1 
and show different signaling properties.  We report here that T316R represents a 
true binding-deficient Nrp1 mutant that will be useful for future studies. 
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Figure 6.6: The HBD of VEGF-A is responsible for selective binding to the 
Nrp1 b1 domain.   
Exon eight encoded residues mediate high-affinity binding whereas exon seven 
encoded residues primarily govern selectivity. 
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 Exon seven encoded residues are also found to directly physically interact 
with Nrp1.  In particular, we show that E154 directly physically engages T299 in 
the L1 loop of Nrp1, resulting in enhanced and selective Nrp1 binding. The 
importance of this interaction interface is further underlined by the recently 
reported VEGF blocking antibody, Anti-Nrp1B (Liang et al., 2007).  Surprisingly, 
this antibody was shown not to block the expected C-terminal arginine binding site 
of the b1 domain.  Instead it binds to residues in the nearby loops including T299 
of the Nrp1 L1 loop (Appleton et al., 2007).  These data reveal that Anti-Nrp1B 
engages a binding site on Nrp1 that is shared with VEGF-A164, thus explaining its 
ability to potently inhibit VEGF-A binding to Nrp1. 
 It is interesting to note that the other VEGF family members that signal via 
Nrp1 also possess conserved electronegative residues at positions analogous to 
E154: D158 in VEGF-B167 and E194 in placental growth factor 3 (PlGF) isoform-3.  
This suggests that electrostatic repulsion between VEGF family members and 
Nrp2 may be a general mechanism governing ligand binding selectivity.   
 While the Nrp2 L1 loop chimera resulted in increased VEGF-A164 binding 
(data not shown), the observed binding is still significantly lower than that observed 
for wild-type Nrp1.  Consistent with this observation, mutating R287 and N290 of 
Nrp2, which are immediately N-terminal to the L1 loop, has been reported to 
enhance the binding of VEGF-A to Nrp2 (Geretti et al., 2007).  Since the L1 loop 
of Nrp2 is highly conserved, it will also be interesting to explore if there are distinct 
mechanisms that promote selective Nrp2 binding by its in vivo ligands VEGF-C 
and VEGF-D.  Indeed, there may be Nrp-dependent physical mechanisms 
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differentiating Nrp1 dependent angiogenesis and Nrp2 dependent 
lymphangiogenesis.  This also suggests that design of specific Nrp inhibitors that 
exploit the difference in the L1 loop may be attainable. 
 The current Chapter and Chapter 6 have focused on understanding the 
mechanism of Nrp binding to the VEGF family of ligands. Earlier Chapters 
(Chapters 3-4) have provided the molecular basis for Sema/Nrp binding. We have 
found both distinct and overlapping mechanisms that facilitate differential ligand 
binding to the Nrp family. These data led us to consider how inhibitory modalities 
could be designed to selectively inhibit one family of ligands over another. 
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Table 6.1: Data collection and refinement statistics 
Data Collection 
Beamline APS 22-ID 
Wavelength 1.0000 
Space group P43 
Unit cell parameters (a, b, c)  114.97, 114.97, 50.94 
Unique reflections 18014 
Completeness (%) 91.5(55.4) 
Resolution (Å) 2.65(2.74-2.65) 
Rmerge (%) 12.2(53.9) 
Redundancy 4.3(1.7) 
I/σ(I) 11.4(2.02) 
Refinement  
Resolution limits (Å) 20.0(2.65) 
No. reflections/no. to compute Rfree 17074/916 
R(Rfree) 21.2(26.7) 
No. protein residues 432 
No. solvent/ion molecules 19 
No. phosphate molecules 1 
RMSD Bond, Å 0.005 
RMSD Angle, ° 1.01 
Ramachandran outlier/favored (%) 0/96 
Residues with bad bonds/angles (%) 0/0 
Rotamer outliers (%) 0.26 
 
         Table 6.1: Data collection and refinement statistics for Chapter 6 
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CHAPTER 7: MECHANISM OF SELECTIVE VEGF-A BINDING BY NRP1 
REVEALS A BASIS FOR SPECIFIC LIGAND INHIBITION 
Introduction 
 The Nrp family of receptors coordinate ligand-binding events that mediate 
endothelial cell migration and proliferation and neuronal chemorepulsion (reviewed 
in (Zachary et al., 2009)). There are two Nrp homologues, Nrp1 and Nrp2, which 
share the same overall domain architecture with 44% identity in their primary 
sequence.  Nrp ligands include the VEGF family of pro-angiogenic cytokines 
(Soker et al., 1998) and the Sema3 family (He and Tessier-Lavigne, 1997; 
Kolodkin et al., 1997) of axon guidance molecules (Nakamura et al., 1998). Both 
VEGF and Sema3 family of ligands are composed of multiple genes, splice forms, 
and proteolytic products with different receptor binding specificity and physiological 
function.  
 Soluble receptors capable of sequestering specific ligands are an attractive 
modality for blocking ligand-dependent signaling pathways. VEGF-Trap, a soluble 
chimera of VEGFR, containing the domains necessary for ligand binding (Holash 
et al., 2002), has been approved for use as a clinical agent blocking VEGF-A 
dependent angiogenesis (Stewart et al., 2012).  The identification of endogenously 
expressed soluble Nrp receptors (sNrp) with anti-tumor activity (Gagnon et al., 
2000) has prompted interest in the use of engineered Nrp molecules as specific 
pathway inhibitors. It was recently reported that mutation to the Nrp2-b1 domain 
enhances its ability to bind VEGF-A (Geretti et al., 2007) and that administration 
of this truncated receptor effectively antagonizes VEGF-A dependent angiogenic 
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signaling (Geretti et al., 2010). A Sema3 specific inhibitor would be of significant 
utility.  While Sema3 mediated repulsive cues are essential during development, 
they pose a significant barrier to axonal regrowth following injury (de Wit and 
Verhaagen, 2003).  This is particularly the case in repair following spinal cord 
injury.  In response to spinal cord injury a glial scar forms that serves as a barrier 
to regenerating axons.  Sema3 family members are produced by meningeal cells 
located in the glial scar and are a major component of the repulsive cues that 
prevent axonal regeneration (De Winter et al., 2002; Niclou et al., 2003).  Blocking 
inhibitory cues represents one fundamental mode of regenerative therapy for 
partial cord injuries (Fawcett, 2006). However, due to limited understanding of the 
determinants of Nrp binding specificity, no soluble Nrp-trap exists that is specific 
for Sema3. 
 The conserved Nrp architecture provides Nrp homologues with the ability to 
bind ligands using a common binding mode. As demonstrated in Chapters 5 and 
6, the b1 coagulation factor domain of Nrp1 and Nrp2 contains a conserved cleft 
optimally suited for binding a C-terminal arginine that is necessary for ligand 
binding (Parker et al., 2012c; Starzec et al., 2007; Vander Kooi et al., 2007). All 
VEGF family members contain a C-terminal arginine. Additionally, in Chapters 3 
and 4 we demonstrated that all Sema3 family members contain at least one 
conserved furin recognition sequence that is endogenously cleaved to liberate a 
C-terminal arginine (Adams et al., 1997; Parker et al., 2010). Indeed, binding to 
this shared site underlies the observed competition between VEGF and Sema3 
(Geretti et al., 2007; Parker et al., 2010).   
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 In physiological context, physical and functional specificity is observed 
between receptor-ligand pairs. Nrp1 acts as the functional receptor for VEGF-A 
(Soker et al., 1998) and Sema3A (He and Tessier-Lavigne, 1997; Kolodkin et al., 
1997) and Nrp2 acts as the functional receptor for VEGF-C (Karkkainen et al., 
2001) and Sema3F (Giger et al., 1998). The mechanism underlying specific 
Sema3 family member binding by Nrp1 and Nrp2 has been shown to involve dual-
site binding. The Nrp b1 domain binding to the Sema3 C-terminal domain is 
necessary for high-affinity binding but does not display specificity for Nrp1 or Nrp2 
(Giger et al., 1998; Parker et al., 2010).  Secondarily, the N-terminal a1 domain of 
Nrp1 and Nrp2 selectively binds the sema domain of different Sema3 family 
members (Chen et al., 1998; Koppel et al., 1997; Merte et al., 2010).  Indeed, a 
Sema3 binding-deficient Nrp has been reported which disrupts the unique a1/sema 
interaction (Gu et al., 2002). However, since there is no known secondary binding 
site, the basis for specificity in VEGF binding remains unclear. 
 It was recently demonstrated that the essential VEGF-A164/165 (VEGF-A) 
isoform binds preferentially to Nrp1 (Parker et al., 2012c). The C-terminal arginine 
binding cleft of the Nrp1-b1 domain is formed by three loops which are a common 
feature among coagulation factor domains. While the cleft is conserved, a 
significant number of residues surrounding this binding pocket differ between Nrp1 
and Nrp2 and may contribute to the observed ligand binding specificity. Indeed, 
the L1 loop of the Nrp b1 domain has been shown to contribute to the observed 
preferential binding of VEGF-A to Nrp1 (Parker et al., 2012c). However, this 
interaction alone is insufficient to explain the marked difference in potency of 
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VEGF-A binding to Nrp1 and Nrp2, therefore other molecular determinants of this 
preferential binding must exist. The recently reported Nrp2 mutation, when Nrp2 
R287 is replaced with the corresponding Nrp1 E285, shows enhanced VEGF-A 
binding and, importantly, unchanged binding to Sema3F (Geretti et al., 2007). 
Together, these data suggest that the Nrp b1 domain contains distinct features 
that govern specific ligand binding and could be exploited to produce specific 
inhibitors of Nrp ligands. By understanding how selective VEGF binding is 
achieved, and whether these regions also affect Sema3 binding, a Nrp molecule 
that specifically bound Sema3 and blocked Sema3 repulsive cues could be 
designed as a potentially important therapeutic tool.  
 In the present study we determined the basis for preferential Nrp1 binding 
to VEGF-A. Mutagenesis of residues surrounding the shared C-terminal arginine 
binding pocket identifies residues that differ between Nrp1 and Nrp2 and underlie 
the observed VEGF-A specificity.  A chimeric Nrp2, which combines the identified 
mutations, is capable of binding VEGF-A similarly to Nrp1 whereas a chimeric Nrp1 
shows significant loss of VEGF-A binding. We further show that Nrp1 and Nrp2 
both bind Sema3F with similar affinity and that both Nrp2 and the chimeric Nrp1 
can selectively sequester Sema3. These data establish that unique mechanisms 
are used by Sema3 and VEGF-A to mediate specific Nrp binding, revealing a basis 
for the use of engineered Nrp molecules as selective inhibitors of Sema3. 
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Results 
Soluble Nrp1 selectively inhibits VEGF-A 
 To assay the inhibitory potency of Nrp1 and Nrp2, we tested the ability of 
Nrp1 and Nrp2 to inhibit VEGF-A binding to Nrp1 affinity plates in a dose 
dependent manner (Figure 7.1). Nrp1 was able to potently inhibit the binding of 
VEGF-A to Nrp1 affinity plates with an IC50 = 1.8 μM (log IC50 = -5.7 ± 0.2) (black 
line, Figure 7.1).  In contrast, Nrp2 was able to inhibit binding only at the highest 
concentrations with an IC50≈ 310 μM (log IC50 = -3.5 ± 0.4) (grey line, Figure 7.1). 
Each experiment was performed in triplicate with unique protein preparations to 
provide a direct measurement of inter-assay variability, with 11% inter-assay 
variability observed for Nrp1 compared to 3.5% intra-assay variability.  These data 
demonstrate, both qualitatively and quantitatively, the robust quality and 
reproducibility of the reported data. The greater than 100-fold difference in IC50 
between Nrp1 and Nrp2 is consistent with the previously reported VEGF binding 
selectivity (Parker et al., 2012c). 
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Figure 7.1: Nrp1 selectively inhibits VEGF-A binding.  
The ability of Nrp1 and Nrp2 to selectively sequester AP-VEGF-A from Nrp1 
adsorbed on affinity plates was assessed. The amount of retained AP-VEGF-A 
was measured and the Nrp concentration recorded where half-inhibition was 
achieved. Nrp1 inhibited the binding of VEGF-A with an IC50 = 1.8 μM (black line). 
Inhibition by Nrp2 was seen only at the highest concentration of protein attainable 
with an estimated IC50 ≈ 310 μM (grey line). Experiments were performed in 
triplicate and reported as the mean ± 1 S.D.    
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Identification of the regions of Nrp1 that confer selective VEGF-A binding 
 The selective ability of Nrp1 to inhibit VEGF-A binding led us to consider the 
mechanism of this specificity. The predominant Nrp structural determinants 
mediating VEGF-A binding have been localized to domain b1 (Geretti et al., 2007; 
Gu et al., 2002; Parker et al., 2012c). The b1 domains of Nrp1 and Nrp2 are 45% 
identical. Conserved between both are the residues which form the C-terminal 
arginine binding pocket demonstrated to be essential for VEGF-A/Nrp binding 
(Vander Kooi et al., 2007) (Figure 7.2, A, asterisk). Alignment of Nrp1 and Nrp2 
domain b1 reveals diversity in the primary sequence conservation of regions 
surrounding the binding pocket.  There are three different categories of residues: 
those that are well conserved in both Nrp1 and Nrp2, those that are not well 
conserved, and those which are distinct between Nrp1 and Nrp2 but well 
conserved within each ortholog. We hypothesized that residues in this last 
category likely underlie the observed specific Nrp1/VEGF-A binding.  Further, 
residues nearby the binding pocket, especially those in the coagulation-factor 
loops (L1-L3) often utilized in ligand binding in coagulation-factor domain proteins 
(Fuentes-Prior et al., 2002), most likely underlie specific binding.  
 Based on these two criteria, i.e., that residues are separately conserved 
within Nrp1 and Nrp2 and that they are nearby the binding site, four regions were 
selected: Nrp1:E285/Nrp2:R287, Nrp1:299-TN-300/Nrp2:301-DGR-303, 
Nrp1:304-ER-305/Nrp2:307-QQ-308, and Nrp1:350-KKK-352/Nrp2:353-QNG-355 
(Figure 7.2, B). Mutant proteins were produced by swapping the selected 
sequences between the two Nrp homologues. Nrp residues that contribute to the 
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observed specificity would be expected to reduce Nrp1 binding and enhance Nrp2 
binding when reversed. These chimeric Nrp molecules were expressed with an N-
terminal AP tag. The binding of AP-Nrp constructs to VEGF-A affinity plates was 
measured and normalized relative to wild-type Nrp1 or Nrp2 binding. Reduced 
binding to VEGF-A was observed for all Nrp1 chimeras relative to wild-type Nrp1 
(Figure 7.2, C), suggesting a role of these sequences in VEGF-A binding. Three 
of the four Nrp2 chimeras showed enhanced affinity for VEGF-A relative to wild-
type Nrp2 (Figure 7.2, D). The reduction in VEGF-A binding for both Nrp1 ER/QQ 
and Nrp2 QQ/ER suggests that these mutations may destabilize the protein and 
this mutation was therefore excluded from further study. These results suggest that 
E285, 299-TN-300, and 350-KKK-352 of the Nrp1-b1 domain contribute to 
selective VEGF-A binding. 
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Figure 7.2: Nrp1 residues mediate specific VEGF-A binding.  
(A) Alignment of orthologous Nrp1 and Nrp2 b1 domains shows conservation of 
residues critical for C-terminal arginine binding (marked with a *) but variability 
within regions surrounding the interloop cleft (orange: Nrp1:E285/Nrp2:R287 
(Geretti et al., 2007); green: Nrp1:299-TN-300/Nrp2:301-DGR-303; blue: 
Nrp1:304-ER-305/Nrp2:307-QQ-308; purple: Nrp1:350-KKK-352/Nrp2:353-QNG-
355). Below the alignment is a conservation histogram illustrating identity across 
the displayed sequences. (B) Surface representation of the Nrp b1 domain reveals 
that the direct VEGF-A binding region (gold) (Parker et al., 2012c) is closely 
associated with the selected regions (colored according to 2A) in three-
dimensional space. (C) VEGF-A binding of Nrp1 mutants reveals loss of binding 
for each mutant protein compared to wild-type. Retained AP-Nrp1 binding is 
reported as the percent of retained wild-type AP-Nrp1. (D) Determination of the 
VEGF-A binding capacity of Nrp2 mutants reveals that three of the four Nrp2 
chimeras show enhanced VEGF-A binding compared to wild-type. Retained AP-
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Nrp2 binding is reported as the percent of retained wild-type AP-Nrp2. Experiments 
were performed in triplicate and reported as the mean ± 1 S.D.  
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Nrp2Chimera inhibits VEGF-A binding  
 To assess whether the identified loops compose the predominant features 
of the Nrp1-b1 domain that confer specific VEGF-A binding, we generated a Nrp1 
and Nrp2 molecule which incorporated all three different mutations in a single 
construct, termed Nrp1Chimera and Nrp2Chimera.  To ensure that the mutant proteins 
were well folded, CD was utilized to assess wild-type and chimeric constructs 
(Figure 7.3, A). All proteins produce spectra consistent with the expected β-
sandwich architecture of the protein.  Further, wild-type and mutant proteins show 
superimposable spectra demonstrating that the mutations are not structurally 
deleterious. As a quantitative measure of the selectivity of NrpChimera proteins for 
VEGF-A, we assayed the potency of Nrp1Chimera and Nrp2Chimera in inhibiting AP-
VEGF-A binding to Nrp1 affinity plates (Figure 7.3, B). The dose-dependent ability 
of these constructs to inhibit VEGF-A binding was compared to wild-type Nrp1 and 
Nrp2 (Figure 7.1). The Nrp1Chimera showed a significant loss in potency, with an 
IC50 = 62 μM (log IC50= -4.2 ± 0.1) (blue line, Figure 7.3, B), an over 30-fold loss in 
potency compared to Nrp1 (black line, Figure 7.1). Strikingly, Nrp2Chimera gained 
fifty-fold potency relative to Nrp2, with an IC50 = 3.9 μM  (log IC50 = -5.4 ± 0.2) 
(green line, Figure 7.3, B), nearly to the level observed for wild-type Nrp1.  
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Figure 7.3: NrpChimera molecules exhibit reversed VEGF-A specificity.  
(A) The secondary structure of WT Nrp and NrpChimera was assessed by CD. The 
overlapping spectra of NrpChimera with wild-type Nrp demonstrate that the 
incorporated mutations are not structurally deleterious. (B) Nrp1Chimera (blue line) 
and Nrp2Chimera (green line) were tested for their ability to selectively sequester AP-
VEGF-A from Nrp1 adsorbed on affinity plates. The NrpChimera molecules show 
reversed VEGF-A specificity with Nrp1Chimera having a marked reduction in 
inhibitory potency (IC50 = 62 μM) and Nrp2Chimera exhibiting a significant gain in 
potency (IC50 = 3.9 μM). Wild-type Nrp1 (black dotted line, IC50 = 1.8 μM) and Nrp2 
(grey dotted line, IC50 ≈ 310 μM) are shown for comparison (data from Figure 7.1). 
Experiments were performed in triplicate and reported as the mean ± 1 S.D.   
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Nrp1 and Nrp2 equivalently inhibit Sema3F binding 
 VEGF and Sema3 are the two major ligand families of Nrp receptors. The 
Sema3 family of ligands has been demonstrated to bind Nrp receptors via a dual-
site binding mechanism. The Sema3 semaphorin domain mediates specific ligand 
binding via the Nrp a1 domain (Koppel et al., 1997) and the Sema3 basic C-
terminus mediates common high-affinity binding to the Nrp b1b2 domains (Gu et 
al., 2002).  To confirm that the Nrp1 and Nrp2 b1b2 domains bind to Sema3, and 
that they do not display specificity, we measured their ability to inhibit the binding 
of AP-Sema3F to Nrp1. Both Nrp1 and Nrp2 showed a dose-dependent inhibition 
of AP-Sema3F binding with equivalent observed potency for Nrp1, IC50 = 2.0 μM 
(log IC50 = -5.7 ± 0.1), and Nrp2, IC50 = 2.7 μM (log IC50 = -5.6 ± 0.3) (Figure 7.4, 
A).  To confirm that this interaction is mediated by the C-terminal domains of 
Sema3, we assayed the ability of Nrp1 and Nrp2 b1b2 domains to inhibit the 
binding of AP-Sema3F-Ig-basic to Nrp1. Consistent with the potency against full-
length Sema3F, Nrp1 inhibited AP-Sema3F-Ig-basic binding with an IC50 = 1.2 μM 
(log IC50 = -5.9 ± 0.1) and Nrp2 inhibited AP-Sema3F-Ig-basic binding with an IC50 
= 6.2 μM (log IC50 = -5.2 ± 0.2) (Figure 7.4, B).  
 These data demonstrate that the b1b2 domain of Nrp1 and Nrp2 contain 
structural determinants capable of C-terminal Sema3F binding and that this 
binding does not show specific binding to the two Nrp homologues.  To confirm 
that the interaction between the basic domain of Sema3F and Nrp1-b1b2 is 
conserved across the Sema3 family, and that this interaction site overlaps with that 
for VEGF-A, we measured the ability of a peptide corresponding to the C-terminus 
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of both Sema3F and Sema3A to inhibit VEGF-A binding (Figure 7.4, C). C-
furSema3F and C-furSema3A, peptides corresponding to the furin-activated forms 
of Sema3F and Sema3A, respectively, were assayed for their ability to 
competitively inhibit the binding of VEGF-A.  Both peptides showed potent, dose-
dependent inhibition of AP-VEGF-A binding with IC50 = 22 nM (log IC50 = -7.7 ± 
0.04) and 67 nM (log IC50 = -7.2 ± 0.04) for C-furSema3F and C-furSema3A, 
respectively.  These data confirm that the Sema3 family of ligands utilize their basic 
C-terminus for equivalent high-affinity binding to the Nrp b1b2 domains, and that 
this binding is competitive with that of VEGF-A. 
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Figure 7.4: Nrp inhibits Sema3F binding through interaction with the C-
terminal basic domain.  
(A) Nrp1 and Nrp2 dependent inhibition of AP-Sema3F binding to Nrp1 affinity 
plates was measured. Both Nrp homologues showed similar ability to compete for 
AP-Sema3F, with Nrp1 inhibiting with an IC50 = 2.0 μM and Nrp2 with an IC50 = 
2.7. μM. (B) The ability of Nrp1 and Nrp2 to selectively sequester AP-Sema3F-Ig-
basic from Nrp1 adsorbed on affinity plates was assessed. The amount of retained 
AP-Sema3F-Ig-basic was measured and the Nrp concentration recorded where 
half-inhibition was achieved. Nrp1 (black line) and Nrp2 (grey line) had similar 
ability for inhibiting Sema3F binding with IC50 = 1.2 μM and IC50 = 6.2 μM, 
respectively. (C) Two peptides corresponding to the C-terminal basic domain of 
Sema3A (C-furSema3A) and Sema3F (C-furSema3F) were analyzed for their 
ability to inhibit AP-VEGF-A binding to Nrp1 affinity plates. Both peptides potently 
inhibited binding, with an IC50 = 22nM and 67nM for C-furSema3F and C-
furSema3A, respectively. Experiments were performed in triplicate and reported 
as the mean ± 1 S.D.   
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Nrp2 and Nrp1Chimera relieve C-furSema mediated inhibition of AP-VEGF-A 
binding to Nrp1 
 Nrp1 and Nrp2 display similar affinity for Sema3F (Figure 7.4, A & B) but 
Nrp2 has markedly reduced binding to VEGF-A relative to Nrp1 (Figure 7.1). This 
data suggests that Nrp2 may be a potent and specific inhibitor of Sema3 binding 
to Nrp receptors. To demonstrate the use of Nrp2 as a selective Sema3 inhibitor, 
we assayed the ability of Nrp2 to selectively relieve Sema3-dependent inhibition 
of VEGF-A binding. Selectivity would be demonstrated by a reduction of C-
furSema mediated-inhibition and resultant gain in AP-VEGF-A binding to Nrp1 
affinity plates.  Nrp1 showed no ability to relieve the inhibition of Sema3F-mediated 
inhibition.  In fact, Nrp1 directly sequestered VEGF-A at high Nrp concentrations 
resulting in complete loss of binding as expected (black line, Figure 7.5). 
Remarkably, Nrp2 significantly enhanced the amount of VEGF-A retained on Nrp1 
plates to 63% the level of retention seen in the absence of inhibition (grey line, 
Figure 7.5). This provides direct evidence that Nrp2 is able to directly and 
specifically sequester Sema3.  Similarly, 37% recovery was seen with Nrp1Chimera 
(blue line, Figure 7.5), consistent with the reversal of specificity seen for VEGF-A 
inhibition (Figure 7.3, B). These data demonstrates that the unique mechanisms 
utilized by Nrp to preferentially bind different members of the Sema3 and VEGF 
family ligands can be exploited to create Nrp inhibitors specific for different Nrp 
ligand families. 
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Figure 7.5: Nrp2 and Nrp1Chimera preferentially sequester Sema3F.  
The ability of Nrp1, Nrp2, and Nrp1Chimera to selectively sequester C-furSema was 
determined through combined incubation of Nrp, C-furSema3F, and AP-VEGF-A 
in Nrp1 adsorbed affinity plates. Nrp1 was unable to relieve C-furSema-dependent 
inhibition and completely abolished VEGF-A binding (black line). Conversely, 
titration with Nrp2 promoted 63% recovery of VEGF-A binding demonstrating 
selective sequestration of Sema3F (grey line). Nrp1Chimera also relieved C-
furSema-dependent inhibition, promoting recovery of VEGF-A binding to 37% the 
level of uninhibited VEGF-A (blue line). Experiments were performed in triplicate 
and reported as the mean ± 1 S.D.  
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Discussion 
 These data establish the basis for selective Nrp ligand binding to the b1 
coagulation factor domain of Nrp. While both VEGF and Sema3 ligand families 
share a partially overlapping ligand binding site in the Nrp b1 domain (Parker et 
al., 2010), we demonstrate a series of residues that differ between Nrp1 and Nrp2 
and contribute to the observed specific VEGF-A binding.  
 Nrp2Chimera possesses nearly full reversal of selectivity to the level of Nrp1, 
indicating that the three altered regions represent the predominant regions 
mediating specific VEGF-A binding.  The TN/DGR L1-loop is highly divergent 
between Nrp1 and Nrp2 and possesses the only insertion/deletion in the b1 
domain.  Mutation of this region results in the largest net loss of VEGF-A binding 
to Nrp1, consistent with a direct interaction involving a hydrogen bond between 
Nrp1-T299 and VEGF-A-E154 (Parker et al., 2012c). The KKK/QNG L3-loop 
produces the largest net gain in Nrp2 binding to VEGF-A. Conserved residues in 
the L3 loop form one wall of the C-terminal arginine binding pocket. The non-
conserved KKK/QNG residues do not appear to directly engage VEGF-A in the 
bound form. The residues are, however, very distinct in physical properties with 
the Nrp1 loop being significantly more electropositive. VEGF-A contains a series 
of conserved acidic residues in the C-terminus of its heparin-binding domain, 
including E154 discussed above, which contribute to Nrp binding. This suggests 
that the L3-loop may function by electrostatic steering of VEGF-A.  This may 
represent a general mechanism allowing specific binding of other Nrp1 specific 
ligands such as VEGF-B and placental growth factor (PlGF) that also possess 
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acidic residues in their heparin-binding domains. In contrast, Sema3 family 
members and Nrp2-specific VEGF-C and VEGF-D do not possess these acidic 
residues.  A mutant Nrp2 containing R287E has previously been shown to possess 
enhanced binding to VEGF-A (Geretti et al., 2007). We show that charge reversal 
produces a decrease in Nrp1 binding to VEGF-A indicating a direct contribution to 
ligand binding selectivity.  Geretti and colleagues proposed that this may be due 
to enhancing the electronegative potential of the b1 domain of Nrp2 favoring 
binding to the electropositive VEGF-A.  R287 is located in a helical region directly 
adjacent to the L1 loop, suggesting that these regions interact to correctly position 
these two structural elements, and thus the critical ligand binding coagulation 
factor loops.  While the NrpChimera molecules substantially reverse the observed 
specificity for VEGF-A, the reversal does not reach the corresponding wild-type 
level and one or more additional regions may also contribute to selective binding. 
    
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Matthew W. Parker 2014 
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CHAPTER 8: MICROPLATE-BASED SCREENING FOR SMALL MOLECULE 
INHIBITORS OF NRP2/VEGF-C INTERACTIONS 
 Collectively, this dissertation has provided molecular details explaining the 
mechanism of Nrp binding to multiple ligands, including Sema3, VEGF-A, and 
VEGF-C. Using structural approaches we have demonstrated the physical basis 
for Nrp1 and Nrp2 binding to the VEGF-A and VEGF-C family of ligands. Thus, we 
are uniquely poised to develop inhibitors of Nrp ligand binding. Indeed, we have 
already demonstrated the use of peptides (Chapters 3, 4, and 6) and soluble 
receptor fragments (Chapters 6 and 7) for VEGF and Sema3 inhibition. However, 
we are interested in expanding our investigation of Nrp inhibitory modalities 
through the development of small molecule inhibitors that would be of significant 
therapeutic interest. 
 Nrp2 inhibition is of particular interest due to its important role in 
tumorigenesis. Nrp2 is highly expressed in lymphatic endothelial cells where it is 
important for physiological lymphangiogenesis and can contribute to pathological 
tumor lymphangiogenesis (Ellis, 2006; Parker et al., 2012a; Stacker et al., 2002).  
Additionally, expression of Nrp2 and its ligand, VEGF-C, are induced in a variety 
of cancer types and their expression is directly correlated with metastasis to 
regional lymph nodes and advanced stage disease. Thus, blocking Nrp2 activation 
by VEGF-C represents a promising anti-lymphangiogenesis therapeutic strategy. 
Mature VEGF-C, produced through proteolytic removal of N- and C-terminal pro-
peptides, binds domains b1b2 of Nrp2 (Karpanen et al., 2006). A number of C-
terminal arginine containing molecules have been identified as inhibitors of 
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Nrp/ligand binding (Parker et al., 2013).  However, these compounds have limited 
potency and thus identification of inhibitors that target secondary binding sites are 
of significant interest (Guo et al., 2013). To identify novel small molecule inhibitors 
of VEGF-C binding to Nrp2-b1b2, we developed and optimized an assay that 
utilizes Nrp2-affinity plates and an alkaline phosphatase (AP) fusion of VEGF-C 
(AP-VEGF-C) for detection of competitive inhibitors of ligand binding. We used this 
assay to screen the National Institutes of Health (NIH) Clinical Collection, provided 
through the NIH Molecular Libraries Roadmap Initiative, and we report the 
identification of three inhibitors of VEGF-C binding to Nrp2.  
 To make Nrp2-b1b2-affinity plates, we expressed domains b1b2 of human 
Nrp2 (Nrp2-b1b2, residues 276-595) in Escherichia coli (E. coli) strain Rosetta 
Gami-2(DE3) (Novagen/EMD Millipore, Billerica, MA) as a hexa-histidine fusion 
protein from pET28b (Novagen/EMD Millipore). Nrp2-b1b2 was purified in a two-
step process via immobilized metal affinity chromatography (IMAC) (HIS-Select 
HF Nickel Affinity Gel, Sigma-Aldrich, St. Louis, MO) followed by heparin affinity 
chromatography (HiTrap Heparin HP, GE Healthcare Life Sciences, Pittsburgh, 
PA) (Vander Kooi et al., 2007). Purified Nrp2-b1b2 was then diluted to 50 μg/mL 
with 50 mM Na2CO3 pH 10.4 and immediately added to 96-well protein high-bind 
microplates (Plate #9018, Corning, Corning, NY) and incubated for 1 h at 37°C. 
Bovine serum albumin (BSA) (Simga-Aldrich) was used to coat control wells. The 
plate was then aspirated, washed 5x 100 μL with PBS-T (phosphate buffered 
saline, 0.1% Tween 20), and stored with 100 μL PBS-T at 4°C. To detect VEGF-C 
binding to Nrp2-affinity plates, we produced mature mouse VEGF-C (residues 108-
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223) fused at its N-terminus to the reporter gene alkaline phosphatase (AP) (AP-
VEGF-C). AP-VEGF-C was expressed via PEI mediated transient transfection of 
Chinese hamster ovary suspension cells (CHO-S) (Aricescu et al., 2006; Longo et 
al., 2013) from the pAPtag-5 vector (GenHunter Corporation, Nashville, TN). AP-
VEGF-C conditioned media was then buffer exchanged into assay buffer (50 mM 
NaCl, 200 mM Tris pH 7.4) and concentrated to an activity of 7 x 10-1 u/mL. AP-
VEGF-C binding to Nrp2-b1b2-affinity plates was detected by adding 100 μL of 1X 
AP substrate and the evolution of para-nitrophenol phosphate was monitored by 
measuring 405 nm absorption on a microplate reader. Prior to analysis the 
absorbance of the control wells (BSA-coated) was used to background correct the 
data. 
 The assay conditions for screening, including pH and buffer, salt, and 
DMSO concentration, were optimized. First, we analyzed AP-VEGF-C binding to 
Nrp2-b1b2-affinity plates over a pH range of 3 to 9 (Figure 8.1, A). 100 mM citrate 
was used to buffer samples with a pH less than 6.5 and 100 mM Tris was used to 
buffer samples with a pH greater than 6.5. The highest AP-VEGF-C binding was 
observed as a stable plateau between pH = 5.5 and pH = 8. Reduction of pH below 
5 eventually resulted in a complete loss of binding. The observed pH sensitivity of 
AP-VEGF-C/Nrp2-b1b2 binding is consistent with the known requirement for a C-
terminal arginine in Nrp ligands (Parker et al., 2012b; Vander Kooi et al., 2007). In 
light of the observed sensitivity of AP-VEGF-C/Nrp2-b1b2 binding to extremes in 
pH, we determined the effect of buffer concentration on binding (Figure 8.1, B). 
AP-VEGF-C binding to Nrp2-b1b2-affinity plates was analyzed at physiological pH 
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= 7.4 with Tris concentrations between 0 mM and 500 mM. The assay tolerated a 
range of Tris concentrations, with the highest binding observed at 150 mM.  
Additionally, we determined the effect of ionic strength on AP-VEGF-C/Nrp2-b1b2 
binding (Figure 8.1, C). Binding was measured in 200 mM Tris pH 7.4 over a range 
of NaCl concentrations, from 0 mM to 300 mM. The highest AP-VEGF-C binding 
was observed at 50 mM NaCl and greater than 75% binding was observed for all 
other NaCl concentrations tested. Collectively, we used these data to define the 
assay buffer as 50 mM NaCl, 200 mM Tris pH 7.4 for producing the highest signal-
to-noise while maintaining tight control over pH. 
 As a final optimization step, we determined the effect of dimethylsulfoxide 
(DMSO), a common solvent used in small molecule libraries, on AP-VEGF-C 
binding to Nrp2-b1b2-affinity plates (Figure 8.1, D). AP-VEGF-C was prepared in 
assay buffer and binding to Nrp2-b1b2 was analyzed in the presence of increasing 
concentrations of DMSO, from 0% to 10% (v/v). DMSO markedly inhibited AP-
VEGF-C/Nrp2-b1b2 binding with 60% of AP-VEGF-C binding lost at 2% DMSO. 
Therefore, in order to maintain robust assay signal, a maximum of 2% DMSO was 
not exceeded in subsequent experiments. 
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Figure 8.1: Assay optimization.  
(A) The pH sensitivity of AP-VEGF-C/Nrp2-b1b2 binding was analyzed over a pH 
range of 3 to 9. (B) The effect of increasing Tris concentrations on AP-VEGF-
C/Nrp2-b1b2 was determined. (C) AP-VEGF-C/Nrp2-b1b2 binding was analyzed 
for a range of NaCl concentrations. (D) DMSO tolerance was determined by 
titrating DMSO with AP-VEGF-C and analyzing binding to Nrp2-b1b2-affinity 
plates. 
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 With the optimized assay conditions, we then validated our approach by 
testing the ability of the Nrp-binding inhibitory peptide, ATWLPPR (Parker et al., 
2010; Starzec et al., 2007; Starzec et al., 2006), which was initially identified as a 
competitive inhibitor of Nrp1 ligand binding, to inhibit AP-VEGF-C binding to Nrp2-
b1b2 (Figure 8.2, A).  Serial dilutions of ATWLPPR from 300 μM to 3 μM were 
prepared in assay buffer containing AP-VEGF-C and 2% DMSO. ATWLPPR fully 
inhibited AP-VEGF-C/Nrp2-b1b2 binding with an IC50 = 43 μM. This is consistent 
with the previously published potency of this peptide against Nrp1 (IC50 = 60 μM) 
and confirms that the core ligand binding pocket engaged by ATWLPPR is 
conserved between Nrp1 and Nrp2 (Starzec et al., 2006). These data confirm the 
functionality of our assay in characterizing inhibitors of VEGF-C/Nrp2-b1b2 
binding. 
 C-terminal arginine-like compounds have established efficacy for inhibition 
of VEGF/Nrp binding (Jarvis et al., 2010). However, these compounds suffer from 
limited potency and thus we aimed to identify non-C-terminal arginine-like 
inhibitors. The NIH Clinical Collection is a diverse small molecule library of 
approximately 450 drug-like compounds that have a history of clinical testing with 
known safety profiles. We screened the NIH Clinical Collection for inhibitors of 
VEGF-C/Nrp2-b1b2 binding (Figure 8.2, B, PubChem BioAssay AID: 16941), 
testing each compound at 200 μM (2% DMSO). The quality of the results were 
evaluated by two commonly used parameters in high-throughput screens: signal-
to-noise (S/N) and Z-factor (Z), the latter takes into account both the assay 
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dynamic range and signal variability. By these two parameters our assay was 
defined as high quality with an average across-plate S/N = 32 and Z = 0.55 (Zhang 
et al., 1999). The data were Z-score normalized (rescaled to set the mean signal 
(Σ) = 0 with a standard deviation (σ) = 1) (Malo et al., 2006), thus allowing direct 
comparison of each compound’s activity across different plates. The Z-score for 
each compound was plotted and a stringent “hit” criteria was defined as differing 
by more than 3.5 standard deviations from the mean.  This selection criteria 
restricted hits to <1% of the screened compounds and included only inhibitors 
(Figure 8.2, B, dashed line). Importantly, all hit compounds were tested for the 
ability to directly alter the activity of AP, resulting in a false positive, and no effect 
was observed.  
 Three compounds exceeded the criteria for a hit: Zafirlukast (σ = -5.3), 
dihydrexidine HCl (σ = -4.3), and Actinomycin D (σ = -4.0). Each hit was confirmed 
by preparing a concentrated compound stock (50 mM) in 100% DMSO and 
measuring the inhibitory potency against AP-VEGF-C/Nrp2-b1b2 binding in 
triplicate (Figure 8.2, C). All hit compounds showed greater than 90% inhibition of 
AP-VEGF-C/Nrp2-b1b2 binding and their relative potencies were consistent with 
the initial screen.  Zafirlukast (Santa Cruz Biotechnology, Dallas, TX) was the most 
potent inhibitor with an IC50 = 66 μM, dihydrexidine hydrochloride (Tocris 
Bioscience, Bristol, UK) was the weakest inhibitor (IC50 = 113 μM), and 
Actinomycin D (Tocris Bioscience) fell in between these two compounds (IC50 = 92 
μM). Zileuton (Santa Cruz Biotechnology), a drug structurally distinct from 
Zafirlukast but also a leukotriene receptor antagonist, was tested alongside the 
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compounds and showed no ability to inhibit AP-VEGF-C/Nrp2-b1b2, indicating the 
specific activity of these compounds. 
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Figure 8.2: Screen for small molecule inhibitors.  
(A) The ability of the peptide ATWLPPR to inhibit AP-VEGF-C/Nrp2-b1b2 binding 
was determined. ATWLPPR inhibited binding with an IC50 = 43 μM. (B) The NIH 
Clinical Collection small molecule library was screened for inhibitors of AP-VEGF-
C/Nrp2-b1b2 binding. Three compounds exceeded the hit criteria (dashed line), 
reducing binding by more than 3.5 standard deviations from the mean. (C) Hits 
were validated by titrating each compound with AP-VEGF-C and measuring Nrp2-
b1b2 binding. Zafirlukast, Actinomycin D, and Dihydrexidine inhibited AP-VEGF-
C/Nrp2-b1b2 binding with IC50 = 66, 92, and 113 μM, respectively. Zileuton was 
unable to inhibit binding. (D) Chemical structure of the identified hit compounds. 
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CHAPTER 9: DISCUSSION 
Future Directions of Nrp Research 
 Cumulatively, the work described in this dissertation defines the molecular 
basis for binding of the Sema3 and VEGF family of ligands to the Nrp family of 
essential cell surface receptors. Importantly, we have demonstrated that both Nrp1 
and Nrp2 contain a C-terminal arginine binding pocket used for the high-affinity 
binding of both ligand families along with accessory sites to tune potency and 
specificity. The utilization of a common binding site by both VEGF and Sema3 
underlies their observed competitive binding and provides an explanation for their 
functional competition observed in vivo.  
 Because of the complex interplay of Nrp with other molecules, a number of 
critical areas regarding the mechanism of Nrp function remain to be explored.  Of 
particular interest is the specific role for Nrp in distinct signaling cascades and 
tissue types.  Connected to this is the extent to which Nrp functions by the same 
general mechanism in highly diverse pathways or if there are distinct mechanisms 
employed in different signaling cascades. 
Nrp Function as an Essential Co-receptor 
 The nature of Nrp coupling to signaling receptors to form a functional 
signaling holocomplex is a major area of future research.  In particular, unique 
heterophilic receptor/receptor contacts are likely critical to the formation and 
stability of the complex. Although necessary for signaling, the role of the Nrp MAM 
domain is largely unknown. Thus, the MAM domain might physically couple to 
cognate receptors.  Indeed, the membrane proximal seventh Ig-like domain of 
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VEGFR-2 has been shown to form a dimer required for activation (Ruch et al., 
2007; Yang et al., 2010), which could be coupled to MAM domain function in the 
holo-complex.  Further, the specific function of the transmembrane domain of Nrp 
may be to directly couple to signaling receptors or to allow precise physical 
arrangement of the intracellular domain.  The transmembrane domain of VEGFR-
2 has been demonstrated to facilitate correct orientation of homo-dimers to couple 
ligand binding to receptor activation (Dosch and Ballmer-Hofer).  Nrp may require 
similar specific alignment of the transmembrane domain and may, in fact, directly 
couple to the transmembrane domain of cognate signaling receptors.  Indeed, it is 
possible that the extracellular juxtamembrane, transmembrane, and intracellular 
juxtamembrane domains may coordinately function to physically couple ligand 
binding to receptor activation. 
 The function of the intracellular domain of Nrp and the extent to which Nrp 
can function independently of a canonical signaling receptor, for example VEGFR 
or Plexin, remains to be determined.  Of particular interest are the molecules that 
can form direct interactions or indirectly bridge with Nrp.  While GIPC is clearly a 
critical Nrp adaptor protein, other PDZ-domain proteins have also been suggested 
to function with Nrp.  In particular, Nrp was recently identified as a positive regulator 
of hedgehog signaling (Hillman et al., 2011) and the PDZ-domain protein required 
for this activity is currently being pursued.  Connected to this is the extent to which 
autocrine signaling represents a fundamental mode of Nrp activation in disease, 
with particular interest in the connection to cancer stem cell maintenance.   
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Physical basis for Sema3 function via Nrp receptors 
 We have investigated the molecular basis for Sema3 binding to the Nrp 
family of receptors. In Chapter 3 we demonstrated that the Sema3 family is 
processed at a conserved furin recognition site in the C-terminal domain. This 
processing directly regulates Nrp binding and VEGF competition. Additionally, 
Chapter 4 describes specific differences in the furin recognition site across the 
Sema3 family and how the strength of the consensus site and Nrp binding is 
inversely correlated. While it is clear that only the processed form of Sema3 is able 
to function as a VEGF pathway inhibitor, the role of C-terminal processing of 
Sema3 in axon guidance is an intriguing area that remains to be explored.  The C-
terminal domain of Sema3 is necessary, but not sufficient, for its function in axon 
guidance. Sema3 additionally requires an interaction between its sema domain 
and the a1 domain of Nrp (Gu et al., 2002; Klostermann et al., 1998; Mamluk et 
al., 2002).  It is interesting to note that the C-terminal Fc fusion of Sema3, which 
represents the unprocessed form of Sema3, is able to cause axon repulsion in situ 
(Appleton et al., 2007; Cheng et al., 2004).  Thus, both processed and 
unprocessed forms of Sema3 are able to function in situ in axon guidance.  In vivo, 
furin processing may be solely utilized as a mechanism regulating the anti-
angiogenic activity of Sema3 or it may alter the potency and range of activity of 
Sema3 in axon guidance.  Alternatively, VEGF has well characterized neurotrophic 
and neuroprotective effects and it is possible that furin processing of Sema3 could 
affect the ability of VEGF to compete for Nrp binding on the surface of neuronal 
and glial cells. 
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 While the basis for ligand binding specificity has come into focus through 
our work, the contribution of physical mechanisms governing ligand binding 
selectivity versus tissue specific expression remains to be determined.  The 
physical basis for divalent Sema3 binding to Nrp remains an important unanswered 
question.  Specifically, the contribution and coupling between the a1 and b1 
interaction sites and the effect of post-translational modification by furin to binding 
and signaling remain outstanding questions. 
Intriguingly, these data also have direct implications for the in vivo function 
of differential furin processing in Kallmann’s syndrome, a genetic disease 
characterized by incomplete development of olfactory nerve fibers and defective 
migration of neuroendocrine cells. A recent analysis of patients revealed mutations 
in the Sema3A gene underlying the disease, including R733H (Hanchate et al., 
2012).  R733 is the C-1 residue of the Sema3A.1 furin site (Adams et al., 1997). 
Although R733H was efficiently expressed and secreted, it exhibited a marked and 
significant reduction in its ability to signal (Hanchate et al., 2012). The results 
presented within this dissertation suggest that this mutation would reduce furin 
processing at the Sema3A.1 site, one of three furin consensus sites within the 
basic domain. Thus, differential processing and Nrp engagement of the different 
furin sites has important function in both normal physiology and pathology. Our 
data provide a mechanistic basis for understanding the effect of mutations on both 
furin processing and Nrp binding. 
Semaphorin-like proteins are produced by a variety of viruses that utilize 
molecular mimicry.  Various poxviruses encode SemaV family members, which 
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are sema domain proteins homologous to the N-terminus of semaphorin (Yazdani 
and Terman, 2006).  SemaV family members have been shown to induce changes 
in host cytoskeletal dynamics, thereby altering the adherence and spreading of 
infected cells (Walzer et al., 2005).  It has recently been shown that Nrp is essential 
for HTLV-1 viral entry (Ghez et al., 2006).  The HTLV-1 coat protein is a heparin 
binding protein that directly interacts with Nrp (Lambert et al., 2009).  Further, the 
interaction and infectivity of HTLV-1 can be attenuated by both VEGF-A and 
peptide inhibitors of Nrp (Lambert et al., 2009).  Intriguingly, the HTLV coat protein 
that interacts with Nrp requires furin processing for maturation and infectivity 
(Hasegawa et al., 2002).  From our studies, we suggest that HTLV-1 utilizes 
molecular mimicry of the mature furin processed form of Sema3 to target the 
shared Sema3/VEGF binding site in the b1 domain of Nrp.  This insight provides 
a novel avenue for potential therapeutic intervention in HTLV-1 infected 
individuals. 
Nrp Inhibition in Spinal Cord Injury 
 Nrp function in Sema3 signaling is important not only for physiological axon 
guidance, but also for signaling in spinal cord injury (Pasterkamp and Giger, 2009; 
Zhou et al., 2008).  Following spinal cord injury, a glial scar forms to stabilize and 
seal the wound.  However, the glial scar also serves as a barrier to regenerating 
axons due to production of axon repulsion molecules.  Sema3 expression 
significantly contributes to the inhibitory nature of the glial scar and so inhibitors of 
Nrp-Sema3 signaling hold promise as therapeutics for treatment of spinal cord 
injury (De Winter et al., 2002; Fawcett, 2006; Pasterkamp et al., 1999).  
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 The use of soluble Nrp as a modulator of VEGF-mediated angiogenesis has 
been the target of numerous studies. However, soluble Nrp as a modality for 
blocking the chemorepulsive function of Sema3 is less established even though 
clear clinical applications exist for neutralizing molecules in spinal cord injury 
(Niclou et al., 2006).  The efficacy of targeting this signaling axis is demonstrated 
by a small molecule inhibitor of the Sema3A/Nrp1 interaction (Kikuchi et al., 2003) 
that, when given to rats following spinal cord transection, shows enhanced 
regeneration of axons across the glial scar (Kaneko et al., 2006). Additionally, 
initial work has demonstrated that Nrp2 inhibition allows penetration of axons into 
a model glial scar (Shearer et al., 2003). Two outstanding issues remain to be 
solved.  First, many members of the Sema3 family can mediate this deleterious 
axonal repulsion, so a potent pan-Sema3 inhibitory modality is desired (De Winter 
et al., 2002).  Second, selective inhibition of Sema3 signaling without effecting 
VEGF-A signaling is desired to maximally promote recovery following injury. Nrp2 
molecules engineered for increased potency, by oligomerization with an Fc or 
related strategy, have the potential to be used as selective Sema3-traps. One 
promising approach is to repurpose s9Nrp2B for use against Sema3.  
 Through understanding the molecular basis for Nrp’s specific binding of its 
ligands, engineered soluble Nrp receptors can be designed with specificity for a 
particular ligand. The binding of Sema3F shows little selectivity between Nrp1 and 
Nrp2.  Further, the observed inhibitory potency of Nrp1 for VEGF-A and Sema3F 
is virtually identical in absolute terms.  Thus, Nrp1 was found to be equally capable 
of sequestering both VEGF-A and Sema3F and suggests that Nrp1 has utility as 
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a broad-spectrum Nrp ligand inhibitor. In contrast, Nrp2 is found to selectively 
sequester Sema3F. The reported chimeric Nrps have utility for discriminating 
between the contribution of VEGF-A and Sema3F function in a particular system. 
Previous work has reported Nrp1 mutations in the a1 domain that allow production 
of a VEGF-A selective Nrp1 (Gu et al., 2002).  The Nrp1Chimera reported here 
represents a complimentary molecule that is selective for Sema3F, with utility in 
differentiating between specific effects mediated by the different Nrp1 ligands. 
Additionally, molecules specific for certain members of the Sema3 family could 
potentially be produced by combinatorial approaches using the a1 domain of 
Nrp1/Nrp2 for specificity in combination with the b1 domain of Nrp2. Our studies 
demonstrate the mechanism underlying Nrp coagulation factor domain-mediated 
ligand binding selectivity and advances the search for potent and selective 
inhibitors of Nrp signaling. 
Physical basis for VEGF function via Nrp receptors  
 We have determined the structure of VEGF-A and VEGF-C in complex with 
their cognate Nrp receptor, Nrp1 and Nrp2, respectively. The loss of Nrp binding 
by VEGF-C and VEGF-A C-terminal arginine mutants, or to Nrp mutants with an 
occluded binding pocket, demonstrates the use of a C-terminal arginine for ligand 
engagement. Indeed, both the VEGF-A and VEGF-C free carboxylate forms 
extensive interactions with the Nrp-b1 binding pocket. Interestingly, the C-terminal 
domain is the most variable region within the VEGF family and VEGF-C is not the 
only VEGF family member that, in the absence of post-translational modification, 
lacks a C-terminal arginine. Of the five VEGF family members, three family 
 158 
members contain Nrp-binding isoforms that lack this structural motif (VEGF-C, 
VEGF-D, and VEGF-B186). VEGF-D, a close structural and functional homologue 
of VEGF-C, is processed at an equivalent site in its C-terminus to produce a C-
terminal arginine (Stacker et al., 1999) and thus likely utilizes a similar binding 
mode to Nrp2. This observation provides additional functional insight, as loss of 
VEGF-D C-terminal processing also ablates function in vivo (Harris et al., 2013).  
 The collective results from studies of both VEGF-C (Chapter 5) and VEGF-
A (Chapter 6) raise important questions regarding the function and receptor 
binding properties of the VEGF-B family of pro-angiogenic cytokines. Interestingly, 
there are three VEGF-B isoforms, VEGF-B167, VEGF-B127, and VEGF-B186, all of 
which differ in their C-terminal domain (Olofsson et al., 1996a; Olofsson et al., 
1996b). Characterization of VEGF-B186 demonstrated that it exhibited proteolytic-
dependent binding to Nrp1 and identified the site of proteolysis as R227 (Makinen 
et al., 1999). These data suggest that VEGF-B186 may exhibit a similar mechanism 
of activation as that observed for VEGF-C. Alternatively, VEGF-B167 contains a 
heparin-binding domain similar to VEGF-A165 and VEGF-B127 appears homologous 
to VEGF-A121. Thus, the VEGF-B family contains multiple members that share 
similarities with divergent members of the VEGF family and, as such, represents 
an important area for future research. 
 Our data also suggest a physical basis for the observed functional 
differences of VEGF family members and isoforms within specific VEGF families. 
We have demonstrated that VEGF-A164 selectively physically engages Nrp1 and 
exhibits dramatically reduced binding to Nrp2, thus explaining the functional 
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specificity of VEGF-A164 in angiogenesis. Further, VEGF-A164 is well documented 
as the most potent VEGF-A isoform in stimulating angiogenesis.  It is well 
recognized that VEGFR dimerization, while necessary, is insufficient for activation.  
Indeed, a specific dimeric organization of the juxtamembrane domain of VEGFR-
2 has been shown to be critical to couple ligand binding to intracellular receptor 
activation (Dosch and Ballmer-Hofer; Yang et al., 2010).  It is possible that the 
observed binding imposes specific steric constraints, allowing a stable 
organization of the heterohexameric VEGF-A/Nrp1/VEGFR-2 signaling complex.  
Indeed, the heparin binding residues of the HBD (Krilleke et al., 2007) and Nrp1-
b1 domain (Vander Kooi et al., 2007) are positioned spatially close together in the 
complex.  This spatial orientation would allow binding of a single 
glycosaminoglycan (GAG)/heparin chain by the protein complex and further 
reinforce the specific orientation of the signaling complex.  Our data establishes 
the unique physical engagement of VEGF-A164 by Nrp1 and opens up new 
avenues to explore the specific physical mechanism of Nrp in angiogenesis. 
Nrp Inhibition in Tumor Angiogenesis 
 Inhibitory modalities targeting Nrp1-dependent VEGF-A induced 
angiogenesis have been extensively explored.  A soluble Nrp splice form, 
containing only the ligand binding region of the extracellular domain of Nrp has 
been employed and found to inhibit tumorigenesis (Gagnon et al., 2000).  A 
number of peptides and a synthetic peptidomimetic inhibitor of Nrp have been 
described (Jarvis et al., 2010; Parker et al., 2010; Starzec et al., 2006; von Wronski 
et al., 2006).  Methods to overexpress inhibitory molecules, for example Sema3A, 
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have been reported with promising activity in tumor angiogenesis (Casazza et al., 
2011).  Finally, antibodies targeting both Nrp1 and Nrp2 have been developed that 
show promising activity in animal models with observed devascularization of solid 
tumors and decreases in metastasis (Caunt et al., 2008; Liang et al., 2007).  These 
anti-Nrp antibodies are currently being tested in clinical trials.  Surprisingly, one of 
the observed side effects of administration of the Nrp1 antibody, MNRP1685A, 
was platelet depletion (Weekes et al., 2014).  This was shown to be due to platelet 
activation, aggregation, and clearance. 
While significant effort has been devoted to blocking aberrant VEGF-A 
signaling, only recently has VEGF-C been identified as a promising target for 
cancer therapeutics. Aberrant activation of VEGF-C signaling via Nrp2 is 
associated with cancer initiation, survival, and progression (Ellis, 2006; Stacker et 
al., 2002).  The Nrp2/VEGF-C signaling axis contributes to tumorigenesis via 
multiple mechanisms. Mimicking its physiological function, VEGF-C signaling via 
Nrp2 stimulates lymphatic vessel recruitment to tumors and directly contributes to 
cancer metastasis (Caunt et al., 2008). Importantly, the role of VEGF-C and Nrp2 
in tumorigenesis is not exclusively associated with aberrant lymphangiogenesis. 
Indeed, in situ studies have demonstrated that autocrine VEGF-C signaling in 
breast cancer cells stimulates cellular motility (Timoshenko et al., 2007). Further, 
recent reports indicate that cancer cell survival is enhanced through VEGF-
C/Nrp2-dependent autophagy (Stanton et al., 2012) and that autocrine Nrp2 
signaling maintains the population of cancer stem cells (Goel et al., 2013).  VEGF-
C also functions to protect prostate cancer cells from oxidative stress in a Nrp2-
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dependent fashion (Muders et al., 2009). Thus, selective inhibition of Nrp2 
represents a promising, multipronged anti-cancer therapeutic strategy. 
Secreted splice forms of angiogenic receptors have essential roles in vivo 
(Albuquerque et al., 2009; Ambati et al., 2006; Kendall and Thomas, 1993) and 
have been engineered to serve as therapeutic inhibitors that block aberrant 
pathway activation by ligand sequestration (Stewart, 2012).  In Chapter 5 we 
demonstrate that the alternative Nrp2 splice form, s9Nrp2B, potently sequesters 
VEGF-C and inhibits binding to Nrp2. The biological function and localized tissue-
specific expression of s9Nrp2 is of significant interest.  Indeed, s9Nrp2 may be 
analogous or complement the secreted splice form of VEGFR-2, sVEGFR-2, which 
functions as an endogenous lymphangiogenesis inhibitor in the eye (Albuquerque 
et al., 2009).  VEGF-D also functions in lymphatic angiogenesis and has been 
shown to have partially overlapping biological function with VEGF-C and important 
pathological functions (Haiko et al., 2008; Harris et al., 2013; Karpanen et al., 
2006). The conservation of Nrp2-interacting residues between VEGF-C and 
VEGF-D strongly suggest that s9Nrp2B will equivalently sequester both VEGF-C 
and VEGF-D.  In contrast, Nrp2 is physically and functionally separate from VEGF-
A (Parker et al., 2012b; Parker et al., 2012c).  Thus, s9Nrp2B is likely to selectively 
sequester the lymphangiogenic-specific VEGF family members, VEGF-C and 
VEGF-D.  
Development of Nrp Inhibitors 
This dissertation has demonstrated parallel strategies for inhibiting Nrp ligand 
binding, including peptide inhibitors, soluble receptor fragments, and small 
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molecules. These unique inhibitory modalities provide an important basis for future 
studies aimed at optimizing the selectivity and potency of Nrp inhibitors for use 
therapeutically in cancer and spinal cord injury. 
 Two major classes of peptide-based Nrp inhibitors have been described 
(Starzec et al., 2006; von Wronski et al., 2006).  Both are relatively small 
monomeric peptides (5-7 residues) with modest inhibitory potency (mid-mM).  It 
has been unclear if this modest potency is due to specific features of the peptides 
or if it represents a general problem with this mode of inhibiting angiogenesis.  Our 
results from Chapter 2 reveal that C-furSema is able to inhibit binding of VEGF-A 
to Nrp with an increase in potency of two to three orders of magnitude relative to 
previous inhibitors.  It will be interesting to determine the physical basis for this 
enhanced potency.  It is notable that while dimeric VEGF was found to directly 
antagonize Sema3 mediated growth cone collapse, a monomeric peptide inhibitor 
derived from the C-terminus of VEGF reversed this effect (Cheng et al., 2004).  C-
furSema contains the strictly conserved intermolecular disulfide, and the 
multimeric state of the peptide may well contribute to its enhanced potency.  
Additionally, the C-terminal region of all known anti-angiogenic Sema3s shows 
conservation beyond the terminal 5-7 residues.  This suggests that additional 
binding pockets on Nrp may be employed which are not exploited by current 
generation peptides.  Together, these results strongly suggest that potent peptide 
inhibitors of Nrp can be produced, opening exciting avenues to design novel 
inhibitors based on Sema3F and other endogenous angiogenesis inhibitors. 
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A second inhibitory modality is soluble receptor fragments that function by 
sequestering ligand from the active signaling complex. In Chapters 7 we describe 
a monomeric fragment of Nrp capable of sequestering VEGF and Sema3 with 
modest potency. The practice of engineering inhibitor multimerization to increase 
potency is well established for soluble receptor fragments. Most commonly, soluble 
receptors are dimerized by expression as an Fc fusion protein (e.g. VEGF-trap, 
discussed earlier, Fc-sVEGFR3 (Lin et al., 2005), and Fc-sVEGFR1/2 (Holash et 
al., 2002)). The dimeric soluble fragment of Nrp2 presented in Chapter 7, s9Nrp2B, 
represents a unique mechanism for generation of a multimeric protein that 
maintains the benefits of avidity but does not require introduction of an exogenous 
polypeptide sequence.  s9Nrp2B showed significant gains in potency relative to the 
monomeric inhibitor against VEGF-C and remains to be tested against the Sema3 
family. Importantly, this is likely to function as a selective VEGF-C inhibition as 
VEG-A is physically and functionally separate from Nrp2. Additional optimization 
of s9Nrp2B potency, selectivity, and stability is an important future direction for the 
development of a therapeutically useful inhibitor. 
 In parallel with the strategies described above, we report in Chapter 8 the 
development of a VEGF-C/Nrp2 binding assay that we used to screen a small 
molecule compound library for inhibitors of Nrp2. We identified three novel 
inhibitors of VEGF-C/Nrp2 binding.  Intriguingly, both Actinomycin D and 
Zafirlukast are used to treat disease states, tumor angiogenesis and asthma, 
respectively, where anti-angiogenesis has been suggested to be an important 
beneficial secondary effect of treatment (Lee et al., 2011) (Blumberg, 1974). In 
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both cases, a direct contribution of Nrp inhibition in the biological activities of these 
compounds is an important area for future studies. Additionally, the development 
of this assay opens the door for screening other large chemically diverse small 
molecule libraries to identify more potent inhibitors of VEGF-C function. Notably, 
none of the three molecules identified contain a C-terminal arginine-like moiety, 
thus providing novel lead compounds for optimization and combinatorial 
approaches towards the production of a potent and selective small molecules Nrp2 
inhibitor. Continued development of novel inhibitory modalities targeting the 
different fundamental mechanisms of Nrp action will be both mechanistically 
informative and have direct relevance to human health. 
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